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ABSTRACT 
Francesca Bargiacchi: Molecular Dissection of Breast Luminal Transcription Networks 
(Under the direction of H. Shelton Earp) 
 
 
 
During mammary development, cellular differentiation and lineage commitment to 
various epithelial and mesenchymal cell types are driven by hormonal and paracrine signaling 
mechanisms. Understanding mechanisms that govern differentiation into distinct cell populations 
is critically important for a complete understanding of development and breast tumorigenesis. 
Previous studies have shown that retroviral transduction of fibroblasts with four transcription 
factors can initiate the conversion of a somatic cell into an embryonic stem cell-like state with 
capabilities of differentiating into cell types of all three germ layers. The goal of the proposed 
study was to determine whether mammary specific transcription factors (TFs) could directly 
induce transdifferentiation to an ER+/luminal cell phenotype in mouse embryonic fibroblasts via 
an iPS-type approach. After screening 9 candidate TFs for their abilities to induce various 
epithelial-specific and breast-specific attributes, we focused subsequent efforts on ESR1, 
FOXA1, PGR, and GATA3. In human mammary epithelial cells, ectopic overexpression of these 
TFs had both unique and overlapping contributions toward inducing the expression of genes 
responsible for luminal differentiation. Combining these TFs in fibroblasts created combinations 
that produced a luminal progenitor phenotype as defined by gene expression histological markers 
for epithelial/breast development and functionality. Examination of the gene expression patterns 
induced by these combinations using a classifier of differentiation status identified several genes  
 
 
iv 
that drive a transition toward the luminal subtype. Since there are presently no cell lines or 
mouse models of luminal A/ER+ breast cancers, the creation of such of a line would be of 
tremendous value. 
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CHAPTER 1: MOLECULAR DISSECTION OF BREAST LUMINAL  
TRANSCRIPTION NETWORKS  
Introduction 
The molecular characterization of human breast cancers and normal mammary 
developmental processes has revealed commonalities that have proven to be useful in clinical 
cancer diagnostics and in understanding normal and neoplastic breast biology. During mammary 
development, cellular differentiation and lineage commitment are driven by distinct growth 
cycles under the control of local epithelial and mesenchymal paracrine signaling mechanisms. 
Multipotent stem cells give rise to various luminal and myoepithelial cell types organized in 
lobular and ductal architectures that ultimately comprise normal breast tissue. Likewise, our lab 
and others have established that human breast cancers consist of multiple “intrinsic” subtypes, 
several of which are defined by their similarity to normal mammary cell counterparts on the 
basis of gene expression patterns.  
These tumor subtypes differ in their responses to therapy and survival outcomes. 
Importantly, luminal A tumors are the most common and diagnostically are ER+ and PR+. 
Luminal A tumors tend to grow slowly, and patients with these tumors have an overall better 
prognosis than those with the other subtypes; yet these tumors do not respond well to 
chemotherapeutic agents. In order to better elucidate the phenotypic and genotypic variations 
between the tumor subtypes, researchers have used breast cancer cell lines extensively to 
investigate specific pathobiologies for each, which may help explain clinical variables such as 
prognosis, response to therapies, and sites of metastasis. Unfortunately, luminal A tumors have 
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yet to be successfully propagated in vitro and to be captured as an immortal cell line (with MCF7 
being a luminal B line). Thus, creating new cell lines that capture the pertinent aspects of the 
luminal A cell-type biology would have tremendous value for a better understanding of these 
tumors and for enabling new drug development.  
To address the goal of creating a ER+/luminal A cell line, we propose an approach 
similar to the one taken to develop induced pluripotent stem cells (i.e., iPS cells). In this 
approach, we propose using two different lineage cell lines and transducing them with candidate 
lineage determining genes, in an attempt to transdifferentiate this basal-like cell line into a 
luminal A–like cell line. The nine candidate transcription factors chosen are all highly expressed 
in ER+/luminal A cells and are thought to be luminal lineage-specific factors. Our preliminary 
data suggested that ectopic overexpression of these transcription factors in HMECs have both 
unique and overlapping contributions toward inducing the expression of genes responsible for 
luminal differentiation. One of these transcription factors, GATA3, is expounded upon in 
Chapter 3. The process that results in the development of a luminal-like cell line requires a 
thorough understanding of mammary development in both mice and humans. In addition, 
knowledge of which mouse mammary models are utilized for the study of development is key, 
particularly with regard to gene knockout models, which result in either no mammary system or 
an abrogated one. Concluding the introduction with a discussion regarding 
reprogramming/transdifferentiation emphasizes not only the technical approach of creating the 
cell line but also the biological process necessary to achieve the change in the cell line lineage. 
The aim of this introduction is to give a relevant and meaningful understanding of the 
complexities surrounding reprogramming and defining breast luminal transcriptional regulatory 
mechanisms.  
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1.1 Overview of Mammary Development 
1.1.1 General Process of Development 
In 1758, zoologist Carl Linneaus noted the unique features of the mammary gland and, as 
the father of modern day taxonomy, created a new group he called Mammalia. This new group, 
Mammalia, was based on the merger of two groups: quadrupeds, or animals with 4 feet, and 
aquatic cetaceans, which include dolphins and whales (Oftedal, 2002). It is thought that the 
mammary gland is derived from apocrine glands, particularly ones in the skin. Darwin and others 
postulated that the complex processes involving the development of a lactating gland confer a 
survival benefit for offspring (Oftedal, 2002). In the early 1900s it was discovered that the ovary 
and pituitary glands are involved in mammopoiesis, particularly with regard to the secretion of 
mammotropic substances. Later, in 1928, castrated virgin rabbits were injected with pituitary 
extracts from lactating animals, resulting in lactation and demonstrating that lactogenic stimuli 
could induce lactation in the absence of ovarian hormonal regulation (Stricker and Grueter, 
1928). In order to better understand development in vitro, Klaus Kratochwil isolated mammary 
gland rudiments of 12- to 14-day mouse embryos, typically developed in organ culture, forming 
a developed breast, including supporting adipocytes; however, rudiments taken from 16-day 
embryos failed to develop under the same conditions, suggesting that mammary development in 
mice is a time-specific process (Kratochwil, 1969). While the mid-20th century was a time 
focused on understanding the key players involved in mammopoiesis, as well as the ability to 
grow mammary tissue in vitro, it was not until the late 20th century that the cloning of steroid 
receptors, mechanisms of downstream signaling, and generation of genetically engineered mouse 
models truly matured, offering researchers a plethora of valuable information (Hennighausen and 
Robinson, 2001). The mammary gland, like other reproductive organs, is one that develops 
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principally after birth. Typically under the control of hormones, development occurs through 
distinctive stages throughout the life span of a mammal, starting with the embryo, continuing 
with puberty, and concluding with reproduction. At each developmental stage, there are cues 
specific to that developmental stage that initiate changes in both the mammary cells and the 
surrounding stroma. Functionally speaking, the mammary gland’s role is to provide ample 
nutrition for offspring. Comprised of milk protein and fat, milk also provides immune factors 
such as antibodies that offer some protection to offspring against disease (Rogier et al., 2014). 
The mammary gland halts development after birth, until puberty, with the growth and expansion 
of milk ducts. It matures via lobuloalveolar development during pregnancy. How these intricate 
signaling processes come together at different stages of mammary development will be discussed 
further, with a primary focus on mouse mammary development. There are several reasons for 
this: First, the ability to genetically engineer mice makes them an attractive model to study. 
Second, there are developmental similarities between humans and mice, although it should be 
noted that there are some subtle structural and hormonal differences between the two (Watson 
and Khaled, 2008).  
1.1.2 Mammary Development in the Embryo 
During embryonic development in mice, five pairs of ectodermal placodes appear 
between Days 10 and 11. These placodes then form buds and continually grow until Day 15. 
These buds turn into epithelial cells and once embedded in the mesenchyme, elongate to form 
sprouts. At this point the sprout develops a lumen, or a hollow opening that connects with the 
skin. At the end of pregnancy, the sprout, called the nipple sheath, becomes a gland that invades 
the adjacent fat pad. For an illustration, please see Figure 1.1. 
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Studies have shown that the mesenchyme from the mammary region is responsible for 
the mammary bud’s epithelial development. Initial signals for epithelial development come from 
the mesenchyme and include transcription factors’ estrogen and androgen receptors, Lef-1, 
Msx1, and the growth factors BMP4 and FGF7. These factors are induced in a paracrine fashion 
by the developing bud and are silenced at later stages (Heuberger et al., 1982). As mentioned 
earlier, mammary gland development was derived from apocrine glands from the skin. Hence, 
some of these transcription factors are not unique to the development of the mammary gland. 
Once the bud is formed, Lef-1 and Msx1/2 are turned off, leading to a lack of other ectodermal 
appendages such as teeth and hair (Hennighausen and Robinson, 2001). With the formation of 
the bud comes the elongation of the primary spout, driven largely by the mammary bud’s 
expression of parathyroid hormone related protein (PTHrP). PTHrP signals to the adjacent 
mesenchyme (which expresses PTHrP receptors) to give rise to the nipple. By Day E18.5, 
several small, tree-like glands have developed and are dependent on factors supplied by the fat 
pad. Signaling from PTHrP continues, facilitating the activation of downstream marker BMP4.  
From a mouse model perspective, PTHrP knockout mice exhibit greatly reduced ductal 
branching morphogenesis. Finally, PTHrP and BMP4 induce Msx2 to regulate the suppression of 
hair follicle formation (Watson and Khaled, 2008). The development of the mammary gland 
elicits signals from the nascent mesenchyme, which is the primary driver of epithelial bud 
development, while working synergistically with the epithelial sprout to further differentiate into 
other ectoderm lineages by rapid changes in transcription factor expression. Interestingly, 
development in the mouse arrests at around Day E18.5 and will not continue until puberty, which 
is when branching morphogenesis and lumen formation predominate.  
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1.1.3 Mammary Development During Puberty 
During this time, the development of the mammary gland relies heavily on hormones, 
leading to the creation of a complex ductal network. This complex network is a result of 
branching morphogenesis, which is regulated by the various components of the mammary gland. 
This includes cellular players such as the stromal compartment-fibroblasts, adipocytes, and 
immune cells, as well as the mammary epithelial cells themselves. Hormones and growth factors 
act in both a paracrine and autocrine fashion to control the growth of the ductal network, 
assisting the invasion into the fat pad. At the tip of these ducts are terminal end buds (TEBs), 
which comprise of two layers of cells. The outer layer consists of cap cells, which are highly 
proliferative, hormone receptor-negative cells involved in the remodeling and extension of the 
bud. In contrast, the body cells, which line the inner portion of the TEB and are responsible for 
lumen development, are less proliferative than the cap cells, and are responsive to 
hormonal/lactogenic stimulus. Please see Figure 1.2. In addition, ductal elongation will result in 
bifurcation of the existing ducts to create branches. In the mouse, this process will be complete 
by 10–12 weeks of age. At that point, TEBs have invaded the fat pad to the full extent and 
growth of the branches has ceased (Watson and Khaled, 2008). One of the key regulators of 
ductal morphogenesis is estrogen. Estrogen has two receptors, ESR1 (ERα) and ESR2 (ERβ). 
ERα has been shown to be critical for mouse mammary development, as ERα-null mice fail to 
develop TEBs and the ducts that do form do not invade the fat pad (Mallepell et al., 2006).  
Along with the process of morphogenesis comes lumen formation. Lumen formation is a 
process that occurs early in the development of mammals and continues through organ 
development, particularly in the lungs and kidneys. Lumen formation in the breast is thought to 
form via the death of luminal cells in the space of the TEB. In addition to undergoing apoptosis, 
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cells within the TEB become polarized, recognizing via contact with the basement membrane 
just prior to lumen formation. Once polarity is established, cells that do not become polarized 
undergo apoptosis (Debnath et al., 2002). Some key proteins that regulate polarity and lumen 
formation include ROBO1 and SLIT2. Knockout mouse models with either ROBO1 or SLIT2 
deficiency not only exhibit defects in TEB structure but also ductal abnormalities that result in 
separation between the luminal epithelial and myoepithelial cell layers (Macias et al., 2011). 
These data highlight the complex signals needed for lumen development.  
There are several transcription factors that drive this stage of mammary development. As 
mentioned before, estrogen signaling is critical for branching morphogenesis and becomes an 
invaluable signal for alveologenesis during pregnancy. ERα-null mice not only have reduced 
levels of prolactin, which augments milk production, but also have insufficient progesterone 
synthesis, which is necessary for ductal development (Hennighausen and Robinson, 2001). 
Progesterone mediates its effects on the development of the mammary gland through two main 
isoforms, PR-A and PR-B. Mice lacking both isoforms become anovulatory and develop a 
severely growth-retarded mammary gland. Progesterone signaling controls cell proliferation 
through the activation of the Wnt pathway, promoting alveolar formation (Brisken and Duss, 
2007). Although estrogen mediates much of the branch morphogenesis, its regulation of 
progesterone receptors (PRs) results in the elaborate extension of the branches, known as side 
branching, in the virgin mouse (Fernandez-Valdivia et al., 2009; Ismail et al., 2003). The role of 
estrogen and progesterone signaling will be further discussed in Section 3.  
While a significant portion of mammary development is largely regulated by estrogen 
and progesterone, certain growth factors mediate their actions. The TGF-β family of receptors 
and ligands was first thought to be involved in mammary development in the late 1980s and 
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activation of TGF-β was thought to correlate with hormonal, differentiation status, as well as 
proliferation/apoptosis (Silberstein and Daniel, 1987). Normally TGF-β is expressed throughout 
all phases of mammary development. TGF-β1 is regulated by estrogen and progesterone, and the 
downstream effectors of TGF-β1 regulate morphogenesis in a variety of ways, including 
apoptosis, matrix remodeling, and loss of proliferation (Moses and Barcellos-Hoff, 2011). 
Although TGF-β signaling can induce apoptosis during morphogenesis, within the mammary 
gland it can exert its effects on the stroma via the production of extracellular matrix (ECM) 
(Moses and Barcellos-Hoff, 2011). This production of ECM may be an attempt to control the 
growth of mammary epithelial cells during development (Gomm et al., 1991).  
1.1.4 Pregnancy and Lactation 
During pregnancy, under the regulation of progesterone, the mammary gland must 
undergo morphological change to prepare for lactation. This includes the differentiation of 
specific luminal epithelial cells that can synthesize and secrete milk. Alveologenesis is the 
production of alveoli, or milk sacs, that will store and secrete milk and is under the regulation of 
both progesterone and prolactin (PRL). As mentioned earlier, PGR is critical for this stage of 
development, as PGR-null mice do not form alveoli (Brisken et al., 1998). Because of the 
massive expansion in mammary epithelial cell growth, signals are sent to further define the milk-
producing luminal cells from the contractile-competent myoepithelial cells. The factors that 
control the fates of these cells have not been well defined; however, some studies have shed light 
on the potential regulatory mechanisms. There are studies suggesting that mammary luminal 
development mimics the development and differentiation of T-helper (Th) cells (Khaled et al., 
2007; Watson and Khaled, 2008). Briefly, the idea is that the polarization of Th cells into either 
Th1 or Th2 lineages occurs via the action of cytokines. These cytokines then activate Stat4 and 
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Stat6, whose downstream effector molecule is GATA3. GATA3 is necessary for Th2 
development due to its role in chromatin remodeling and facilitates the expression of IL-4, IL-13, 
and IL-5 cytokines (Watson and Khaled, 2008). Thus, the regulation of these cytokines promotes 
Th2 while suppressing Th1 differentiation. Mouse knockout models of IL-4/IL-13 (responsible 
for Th2 regulation) resulted in reduced proliferation and milk protein production, as well as 
delayed alveolar development during gestation, a similar phenotype to the Stat6 knockout mouse 
model (Khaled et al., 2007). These data also suggested that under lactogenic stimulation, 
expression of Th1 cytokines was suppressed and that the mechanisms that mediate Th2 
development also determine the fate of the mammary luminal epithelial lineage. The IL-4/IL-
13/Stat6/GATA3 pathway in mammary development is illustrated in Figure 1.3. GATA3, a 
potent regulator of alveolar differentiation, is discussed in further detail in Chapter 3. In addition 
to Stat6 signaling, Stat5, a potent downstream signal from prolactin receptor (PRLR), is critical 
for the differentiation of mammary alveoli during pregnancy (Liu et al., 1997). Although the 
mechanisms are still unclear, it appears that Stat5a and Stat6 work in parallel to induce IL-4/IL-
13 expression.  
1.1.5 Involution 
As with pregnancy and lactation, the immune-regulated genes are involved in mouse 
mammary involution, a process of tissue remodeling and cell death. There are two phases of 
involution: the first occurs within hours of weaning and entails the accumulation of milk within 
the alveolar lumen and subsequent decrease of lactogenic hormones, while the second phase is a 
signal initiated by systemic hormonal regulation. This results in a remodeling of the ECM and 
the basement membrane of the ductal-lobular architecture due to the activation of matrix 
metalloproteases. Ultimately, the immune system is then recruited to clear the “debris” (Stein et 
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al., 2004). All of this occurs within 2 weeks post weaning, making involution a quick and 
efficient process in the mouse. Examining Phase 1 in more detail, we determined that this phase 
is responsible for the apoptotic events within the alveolar lumen and is initiated by Stat3 
signaling. Stat3 is activated by the leukemia initiation factor (LIF). Downstream targets of Stat3, 
IGFPB-5 and C/EBPδ have been shown to be instrumental in the apoptotic response. Knockout 
models of these two genes have suggested a diminished ability to undergo involution 
(Thangaraju et al., 2005; Tonner et al., 2002). Cells with activated Stat3 signaling begin to shed, 
filling the lumen and expressing proapoptotic markers such as Caspase-3, Bax, and decreased 
levels of Bcl-x. Other downstream targets of Stat3 ensure that transition to the second phase of 
involution ensues.  
Approximately 48 hours after Phase 1, Phase 2 begins, primarily by remodeling the 
lobulo-ductal architecture. This is achieved by the stromal secretion of matrix metalloproteases, 
which not only degrade the lobulo-ductal supportive matrix but also initiate further apoptosis 
through the detachment of the ECM to the epithelial cells. Adipocytes migrate to the newly 
remodeled matrix and differentiate via MMP3 and plasminogen (Watson, 2006). Ultimately, NF-
κB signaling recruits immune cells, primarily macrophages, to phagocytose and remove the cells 
and debris, a process that involution mediates.  
The four main stages of mouse mammary development have unique roles and complex 
signaling mechanisms regulated by hormones, growth factors, and lactogenic signals. 
Interestingly, certain phases of mammary development, unlike the phases of development of 
most organs in the body, are induced by the voluntary events of pregnancy and involution. Such 
events, as some studies have suggested, may lower a woman’s overall risk for developing 
premenopausal breast cancer (Newcomb et al., 1994), highlighting how development may 
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influence the risk of neoplastic events during child-bearing years. These different stages of 
development also complement the mouse mammary differentiation hierarchy, as the earlier 
stages correspond to a less differentiated (more stem cell-like) phenotype, while lactation is more 
in line with a luminal differentiated phenotype. It is essential in understanding the developmental 
phases especially when trying to recapitulate a mammary epithelial cell line de novo. This will 
be touched upon in Chapter 2.  
1.2 Current Mouse Models of Mammary Development 
1.2.1 Genes Required for Mammary Function 
Mammary gland development and function are tightly controlled processes that are 
heavily regulated by hormones and growth factors both produced by the epithelial and/or stromal 
compartments, as well as by more distant locations such as the ovaries and/or pituitary gland. 
Understanding the critical mediators of development and function involve multiple cell types, 
particularly within the lobulo-ductal network. The focus will be on the myoepithelial and more 
differentiated basal/luminal epithelial cells. There are several considerations when determining 
which mouse model to utilize for the scientific question at hand. First, in which phase of 
development does the scientific interest rest? For example, as mentioned in Section 1, hormonal 
dependence and necessity become apparent during puberty, when such signals are required for 
ductal elongation and morphogenesis. An ERα-knockout model would thus be a poor choice for 
studying embryonic development of the mammary gland.  
Another important consideration is the phenotype of the mouse model. GATA3, a pioneer 
factor known to be necessary for breast luminal development, is also embryonically lethal (Lim 
et al., 2000). An effective way to circumvent this issue is the creation of a conditional knockout, 
in which a mammary specific promoter (MMTV for example) in a Cre-lox transgenic expression 
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system will delete GATA3 when the MMTV promoter is turned on, presumably in breast tissue. 
This method not only assures expression in the tissue types being studied but also prevents the 
effects of the knockout on the overall development of the embryo. More recently, there has been 
interest in comparing normal breast tissue to breast tissue in tumor development. Here, one may 
want to focus on certain cell types, whether myoepithelial in origin or the cell source that gave 
rise to a luminal tumor. Inducible Cre knock-in models for these questions may include the use 
of a KRT14, KRT8, or KRT18 promoter, depending on the mammary cell type desired 
(Keymeulen et al., 2011).  
Some of the key regulators of mammary development and their phenotypic 
characteristics when knocked out are shown in Table 1.1. The essential gene knockout 
developmental models either result in a breast phenotype that is severely abrogated or 
completely defective in morphology and/or function. It is not surprising to see that loss of ERα 
results in not only branching morphogenesis loss but also a loss in overall reproductive function. 
Interestingly, knocking out ERβ in place of ERα results in the normal development of the 
mammary gland, which suggests that both isoforms have unique downstream targets and that 
functional ERβ cannot compensate for the loss of ERα (Couse and Korach, 1999). Loss of both 
reproductive and lactation function is also observed with progesterone receptor and prolactin 
knockout models, suggesting that genes involved with specific developmental cues across 
multiple tissue types may have a profound effect on those systems when lost. Reduced functions 
are even seen in a PRLR-heterozygous knockout mouse model (Ormandy et al., 1997).  
LEF-1, a transcription factor involved in canonical WNT signaling, is a key initiator of placode 
development in embryonic mice. It is also a key regulator of ectodermal lineages, including teeth 
and hair (Kratochwil et al., 2003). Two other LEF-1 downstream targets, MSX1 and MSX2, also 
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arrest mammary development at the embryonic bud stage, however only when both are knocked 
out is bud development arrested. This suggests that both genes may have redundant functions 
when either one is knocked out (Cowin and Wysolmerski, 2010).  
During each stage of development, signaling cues give rise to particular cellular types, be 
it multilineage, as seen in embryonic development, or within a specific lineage, such as epithelial 
differentiation, as seen in pregnancy. During the embryonic stage, the formation of a rudimentary 
gland includes initial bud formation, which gives rise to the mammary epithelial cells. These 
epithelial cells are poorly differentiated and are not hormone dependent at this stage of 
development. Exhibiting a “basal” phenotype, embryonic cells at this phase express Keratin 14 
and have multipotent capabilities. Keratin 14 positive progenitor cells arise from the embryonic 
epidermis at embryonic Day 17 (E17). Studies have shown that at birth, mouse mammary glands 
consist of a small network of rudimentary ducts comprising of myoepithelial and luminal cells. 
The myoepithelial cells are positive for Keratins 5 and 14 and smooth muscle actin (SMA). 
These are considered markers for the basal phenotype seen in both mammary development and 
cancer and will be further discussed later in this chapter.  
Likewise, luminal cells at birth are positive for a different set of keratins, mainly Keratins 
8 and 19. Their multipotent abilities are worth noting since Keratin 14–positive cells isolated 
from the embryonic phase of development can recapitulate all mammary epithelial lineages 
(Keymeulen et al., 2011). The definition of cellular subsets is made possible by in vivo 
reconstitution assays. Such assays allow for the ability to determine mammary-repopulating 
capabilities. This is achieved by injecting cells in limiting dilutions into a cleared mammary fat 
pad (Visvader, 2009). Cells with the ability to regenerate a mammary gland were also shown to 
have self-renewal properties. As mammary epithelial cells become more defined, particularly 
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during puberty and/or pregnancy, such cells lose their self-renewal and multipotent functions. 
Studies have provided evidence for the abilities of both bi- and unipotent progenitor cells that 
could contribute to the expansion of the mammary gland during puberty and pregnancy 
(Keymeulen et al., 2011). Interestingly, others have shown that while prospective alveolar 
progenitors fail to form outgrowths in vivo, when such cells are coinjected with Matrigel into 
mammary fat pads, they in fact can create small, branched mammary structures (Jeselsohn et al., 
2010; Vaillant et al., 2011).  
 There are several markers used to determine cellular plasticity and differentiation in the 
mouse. The four main markers are CD24, CD29 (ITGβ1), CD61 (ITGβ3), and CD49f (ITGα6). 
Initial studies have shown that CD24 is an excellent marker in delineating between epithelial and 
stromal cells (Sell, 2013). Within the mammary epithelial lineage, CD24 expression also 
delineates between the basal (CD24mod/+) and luminal (CD24hi) subpopulations (Sleeman et al., 
2006). Interestingly, the same study also recognized that sorted mouse mammary epithelial cells 
with high CD24 expression had limited repopulation capacity, suggesting that the CD24low cell 
fraction was responsible for the ability to repopulate a mammary gland. CD29hi and CD49fhi 
have been shown to represent cells with repopulation capacity (Wang, 2006).  
 While mammary stem cells (MaSC) exhibit the CD24mod/+/CD29hi/Cd49fhi phenotype, 
these three markers are difficult for use in defining the luminal progenitor phenotype. In 
addition, they also include the myoepithelial and basal progenitor cells. The highest expression 
levels of CD24, as confirmed by fluorescence-activated cell sorting (FACS), occurs in more 
differentiated mammary epithelial cells. Although neither CD29 nor CD49f were good markers 
for capturing the luminal progenitor population, two markers have been determined to define the 
luminal progenitor population, CD61 and CD133 (prominin-1), although CD61 is the more 
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commonly used marker of the two (Asselin-Labat et al., 2007; Sleeman et al., 2006). The mature 
luminal population (CD24+/CD29low/CD49flow/-/CD61-) will have loss of expression of the 
integrins CD29, CD49f, and CD61 and have higher expression of CD24 than the 
MaSC/progenitor cell types (Lim et al., 2010). There will also be few progenitor cells within this 
population (Lim et al., 2010). As a result, luminal cells are considered to be unipotent with no 
self-renewal capabilities (see Figure 1.4).  
 Studies suggest that EpCAM is superior to CD24 as a marker for mouse mammary 
luminal cells. EpCAM is used in place of CD24 in human mammary studies due to its specificity 
for luminal/luminal progenitor populations, as CD24 expression is found in basal progenitor/ 
MaSC and even some stromal cells (Oakes et al., 2014; Smalley, 2015; Visvader, 2009). 
Depending on the experimental question, either marker is considered acceptable for the isolation 
of progenitor/luminal mammary cells; however, if the desire is to study the basal/myoepithelial 
component of the mammary gland, then EpCAM is a better marker for separating those cells 
from the luminal component (Smalley, 2015).  
 Recently, there has been uncertainty with respect to the roles of stem versus progenitor 
cells. Progenitor cells in the mammary gland are thought to be uni-/bipotent and have little to no 
self-renewal capabilities (Rios et al., 2014; Stingl et al., 2001). Meanwhile, mammary stem cells 
are multipotent and have self-renewal capabilities, resulting in asymmetrical division when 
activated. Mammary transplantation assays have shown the presence of multipotent stem cells 
within the TEBs, and while their frequency is low, questions remain regarding their role in 
development during puberty/pregnancy and homeostasis (Keymeulen et al., 2011; Smith, 1996). 
Therefore, the multipotent stem cell is considered to be at the top of the mammary cellular 
hierarchy, giving rise to either bipotent MaSC or to luminal and basal-limited progenitor cells.  
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 Rios and colleagues (2014) determined that bipotent MaSCs could collectively be called 
multipotent MaSCs due to the fact that these cells contributed to the development of alveolar 
branches during pregnancy. Notably, these cells were traced over a couple of pregnancy and 
involution cycles, suggesting that they were involved in ductal remodeling (Rios et al., 2014; 
Visvader et al., 2014). These bipotent MaSCs may also give rise to lineage-specific progenitor 
cells (basal, luminal). Ultimately, these cells have been found to maintain mammary gland 
homeostasis and development, postnatally, instead of the rare multipotent stem cell that had been 
shown to give rise to a completely functional mammary gland (Mark et al., 2006; Visvader et al., 
2014). It is worth mentioning while discussing the subtle nuances between the multi-/bipotent 
progenitor cells and their functions that the characteristics and functions of the differentiated 
luminal cell have been better characterized. Transplantation studies with mammary stem cells 
typically have basal-like characteristics, perhaps in part due to their basal apical location in the 
TEBs and their role of giving rise to a functional ductal network (Smith and Boulanger, 2003).  
 As mentioned earlier, lineage-committed progenitor cells have features that contain either 
basal or luminal characteristics, although some lineage-tracing studies suggest a bipotent 
progenitor may contain features that are passed onto and maintained in its differentiated 
counterparts, as has been seen using Keratin 5–labeled cells (Rios et al., 2014). Keratin 8–labeled 
stem cells have been shown to give rise to a luminal progenitor cell that can give rise to both 
luminal and milk-producing cells. In addition, these labeled cells were found to be self-renewing, 
after as many as 3 pregnancy/involution cycles, indicating that these cells are not being replaced 
by a mammary stem cell (Keymeulen et al., 2011).  
 Luminal cells in the mouse tend to exhibit heterogeneous characteristics; hence only a 
subset of these cells express the Estrogen Receptor (ESR1) (Petersen and Deurs, 1997). It is 
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widely thought that cells expressing ESR1 within the luminal component are rarely activated 
(Clarke et al., 1997); however, others have discovered rare ESR1-positive cycling cells (Booth 
and Smith, 2006). This suggests that not all ESR1-positive cells are quiescent; they may 
represent a minor fraction of the luminal progenitor population. Luminal progenitor (LP) cells 
expressing ESR1 tend to be CD24+/Sca1+/c-kit+. This is in contrast to LP cells without ESR1, 
whose expression of lineage markers’ CD24+/Sca1-/c-kit+ only varies by the loss of Sca1 
(Sleeman et al., 2007).  
 Both LP populations exhibit bipotent capabilities; however, in the mouse at least, ESR1-
expressing LPs appear to have a survival advantage over ESR1-negative LPs in the presence of 
oestrogens. The basal level of oestrogens in the mammary gland is generally low and thus shifts 
the LP population from ESR1-negative to ESR1-expressing luminal cells. The ESR1-positive LP 
cells are likely to be ductal-restricted progenitor due to their expression of ESR1 and FOXA1. 
ESR1 and FOXA1 are known to be involved in ductal, not alveolar, development, which may 
explain why ESR1-negative LP cells have been shown to be alveolar-restricted progenitor cells 
Shehata et al., 2012).  These cells are long living and prepare the gland for pregnancy and 
involution, giving rise to functional differentiated luminal cells (Keymeulen et al., 2011).  
 As luminal cells are composed of different cell types, lineage-tracing studies have been 
performed using an inducible KRT18 reporter (Keymeulen et al., 2011). Like KRT8, KRT18 is a 
marker for luminal cells. KRT18-positive cells in the Keymeulen et al. (2011) study suggest that 
KRT18 cells do not clonally expand, even during pregnancy and lactation. Therefore, it is 
plausible that KRT18-positive cells are committed luminal cells with a low proliferative profile. 
KRT8 and KRT18 are markers that also delineate basal from luminal subtypes in mammary 
tumors (Herschkowitz et al., 2007; Perou et al., 2000; Prat et al., 2010; Ross and Perou, 2001). 
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Differentiated luminal cells will have high CD24 expression, low to moderate CD29 expression, 
and low to no CD61 expression (Sleeman et al., 2006). The functions of 
CD24+/CD29low/mod/CD61- luminal epithelial cells are well defined, as they exhibit two main 
responsibilities: First, ductal luminal cells are responsible for the lining of the duct, which assists 
in draining the lobuloalveolar structures during lactation. Second, during pregnancy, signaling 
cues (more on this in the next section) initiate the production of milk in an otherwise quiescent 
cell, which explains why such differentiated cells are difficult to culture in vitro (Clarke et al., 
1997; Smalley et al., 1998). Consequently, human studies with reduction mammoplasty tissue 
grown in vitro tend to lose some of the key luminal subpopulations, leaving behind a largely 
proliferating mammary epithelial cell with basal-like features (Gordon et al., 2000). More 
recently, new lineage markers used for the separation of subpopulations have been discovered 
within the stem cell hierarchy. While CD24/CD29/CD61 have been instrumental in defining 
populations with repopulation capacity, metabolic activity, and milk-producing function, new 
markers have been shown to help further define the subpopulations, expanding our 
understanding of the layers involved in plasticity, self-renewal, and function (see Table 1.2).  
 The prepubertal and pubertal/gestational development phases are largely defined by their 
dependence on hormones. Unlike the prepubertal phase, hormone dependence occurs after 
puberty and results in ductal elongation and side branching, and in pregnancy, inducing 
alveologenesis and milk production. Mouse experiments involving the surgical ablation of 
hormone-secreting organs from mature female mice have resulted in lack of mammary gland 
development. The organs involved in mammary development, mainly the pituitary gland and the 
ovaries, are responsible for the secretion of the hormones GH, PRL, 17β-estradiol, and 
progesterone.  
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 Subsequent studies have demonstrated that when the pituitary and/or ovaries were 
removed, treatment of mice with 17β-estradiol, progesterone, growth hormone, cortisol, and 
prolactin could recapitulate the development of the gland (Brisken and O’Malley, 2010). The 
steroid 17β-estradiol is one of the most potent and prevalent of the estrogens. Other members of 
the estrogen family include, estrone and estriol, are also present in the mammary gland. The 
effects of these ligands are mediated through two estrogen receptors, ESR1 and ESR2, and when 
bound to a ligand, ESR1 undergoes a conformational change, resulting in its interaction with 
other transcription factors such as AP-1, SP-1, STAT3, or NF-κB (Tanos et al., 2012). ESR1 also 
recruits coactivators and/or corepressors to help promote these transcriptional changes (Moggs 
and Orphanides, 2001). Due to the action of 17β-estradiol, this genomic mechanism of ESR1 
signaling induces expression of amphiregulin (AREG) which is then acted on by ADAM17, a 
protease that cleaves AREG to its secreted form (Sternlicht and Sunnarborg, 2008). Via 
paracrine mechanisms, AREG subsequently binds to the epidermal growth factor receptor 
(EGFR) on fibroblasts, further inducing the expression of various growth factors, including 
several members of the fibroblast growth factor (FGF) family of ligands (Coleman-Krnacik and 
Rosen, 1994). Within the luminal cell, ESR1 signaling is also highly influenced by coregulators, 
which include coactivators and corepressors. This is also the case for progesterone receptor 
(PGR) signaling, which will be discussed next.  
 A fine balance of ESR1 coactivators and corepressors within the cell determines the fate 
of ESR1 signaling. The recruitment of either coactivators/corepressors to the receptor site is 
predicated on the mechanisms of ESR1 activation. Phosphorylation of ESR1 is necessary for 
particular interactions with coactivators, and the consequences can lead to the recruitment of 
other coactivators, thereby increasing the transcriptional activity of ESR1 (Dutertre and Smith, 
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2003; Leo and Chen, 2000). While ESR1 is necessary for mammary development in both mice 
and humans, ESR1 levels in luminal progenitor cells are lower in mice than in humans (Asselin-
Labat et al., 2007; Asselin-Labat et al., 2010; Lim et al., 2009), although the reasons for this are 
not well understood. This may explain, in part, why there are no real ESR1-positive mammary 
models.  
 It is also difficult to study ESR1 signaling in mice, as both the stroma and epithelium 
express ESR1. This is in contrast to the human mammary gland, where ESR1 is uniquely 
expressed in the epithelium. As a result, studies surrounding the role of ESR1 signaling in 
development have been focused on human normal and breast cancer cell lines. Two of the 
critical mediators of ESR1 signaling are FOXA1 and GATA3. Both are considered pioneer 
factors: FOXA1 has been shown to mediate ESR1 binding to a subset of gene promoters whose 
genes are involved in proliferation, such as Cyclin D1 (CCND1) (Eeckhoute et al., 2006, 2007). 
CCND1 is required for proliferation in ESR1/PGR-positive cells in response to progesterone 
stimulation during alveologenesis (Beleut et al., 2010). GATA3, like FOXA1, initiates the 
tethering to promoter regions adjacent to estrogen responsive elements (ERE) prior to ESR1 
binding (Liu et al., 2011). In return, ESR1 binds to EREs in the GATA3 promoter, upregulating 
GATA3 expression (Grober et al., 2011; Jin et al., 2004). GATA3 is also involved in mouse 
mammary differentiation, as Gata3 deletion in alveolar cells during pregnancy leads to a loss in 
alveolar differentiation and failed lactogenesis (Asselin-Labat et al., 2007). ESR1-mediated gene 
repression is controlled through the interaction of ESR1 with NF-κB and C/EBPβ, resulting in 
the down regulation of the proinflammatory gene IL-6 (Ray et al., 1994; Stein and Yang, 1995). 
Treatment with 17β-estradiol in human mammary cells in vitro leads to upregulation in genes 
involved in proliferation (GREB1), secretory development (TFF1, TFF3), or hormonal 
 
 
21 
regulation (PIP) (Wilson et al., 2006). Interestingly, several of these genes are also 
overexpressed in human luminal A/B tumors, which highlights the remarkable similarities 
between normal and tumorigenic genomic profiles.  
 In addition to mammary development, estrogens act on the pituitary gland by stimulating 
prolactin synthesis and secretion. In turn, prolactin controls the synthesis of progesterone and 
induces ESR1 expression in various tissues (Bachelot and Binart, 2007; Frasor and Gibori, 
2003). In order to better understand the direct versus indirect mechanisms behind hormonal 
regulation of the mammary gland, hormone receptor-deficient mouse strains have been 
developed. For the cognate hormone receptors ESR1, ESR2, and PGR, and prolactin receptor 
(PRLR), mice without any of these receptors are in fact viable but have severe reproductive 
abnormalities, including sterility (Bole-Feysot et al., 1998; Hamilton et al., 2014; Ismail et al., 
2003). In the mouse mammary gland, ESR1 is expressed in both the epithelium and the stroma. 
Epithelial ESR1 expression is required for ductal elongation and for subsequent side branching 
in alveologenesis. Studies addressing the necessary role of ESR1 in the stroma were performed 
by grafting ESR1-/- fat pads along with wild-type ESR1 mammary epithelium into the muscle 
wall of mice. The presence of stromal ESR1 was not required for mammary gland development 
(Mallepell et al., 2006).  
 Similar to ESR1 signaling, PGR is also expressed in both the epithelia and the stromal 
tissue of the mammary gland (Tanos et al., 2012). There are two protein isoforms of PGR, PR-A 
and B, which are expressed as a result of transcription from two alternative promoters (Conneely 
et al., 2001). Functional characterization of isoforms A and B have shown that PR-B is required 
for mammary development while PR-A is necessary for reproductive responses to fertility 
(Conneely et al., 2003). The ligand for PGR, progesterone (P4), is produced by the ovaries 
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during the luteal phase of the reproductive cycle, whose role in the mammary gland is the 
promotion of ductal side branching and alveolar development (Graham and Clarke, 1997). PGR 
receptor signaling is thought to be mediated in the mammary gland via a series of signaling 
events. First, progesterone activates PGR-negative cells in the TEBs, undergoing proliferation to 
promote side branching and alveolar development, while the adjacent PGR-positive cells in the 
TEB remain quiescent. Downstream targets of PGR have been implicated as effector genes for 
proliferation and side branching morphogenesis (Obr and Edwards, 2012). These genes include 
Wnt4, amphiregulin, and RANKL, among others. During pregnancy, progesterone suppresses 
differentiation by inhibiting the expression of tight junction proteins until parturition in order to 
assume the proliferative role of alveolar expansion up until lactation. During lactation, 
progesterone levels will decline, allowing for milk production and secretion (Obr and Edwards, 
2012). Currently, the molecular mechanisms regulating tight junctions between luminal cells, 
which progesterone mediates, are unknown.  
 The hormonal regulation of milk production falls under the regulation of two key 
lactogenic hormones: prolactin (PRL) and glucocorticoids. As mentioned earlier, PRL induction 
is regulated by ESR1. Prolactin receptor (PRLR) signaling activates STAT5A via 
phosphorylation by JAK-2. In addition to ESR1, glucocorticoids may also potentiate PRL 
signaling by recruiting glucocorticoid receptors (GR) near STAT5 binding sites. Other 
coactivators of milk protein production, such as C/EBPβ will form a complex with STAT5A and 
GR to help further recruit other proteins involved in chromatin remodeling, allowing for 
transcriptional activity at the β-casein (CSN2) promoter site (Doppler et al., 1990; Kazansky et 
al., 1999; Wyszomierski and Rosen, 2001). ESR1 and PGR-positive cells in the mammary gland 
tend to be quiescent, and a similar phenomenon is seen with STAT5A and PRLR-positive cells 
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(Brisken and Rajaram, 2006). In the presence of progesterone, a STAT5A-PGR complex can 
inhibit activation of downstream genes, importantly β-casein (Buser et al., 2013), highlighting 
the timely importance of progesterone stimulation during pregnancy and lactation.  
1.2.2 Comparing Mammary Development to the Five Intrinsic Subtypes of Breast Cancer 
 Gene expression microarray analysis of human breast cancers has revealed five intrinsic 
molecular subtypes: luminal A, luminal B, basal-like, HER2-enriched, and claudin-low (Perou et 
al., 2000; Prat et al., 2010). Each of these subtypes has unique histological features and different 
responses to therapy and clinical outcomes. The term “intrinsic” subtype was used to 
characterize these tumors in part due to their developmental characteristics (Perou et al., 2000). 
Concerted efforts have been underway for several years now to understand where along the 
breast developmental hierarchy cellular transformation occurs. One of the more prevailing 
thoughts is that a normally quiescent stem cell undergoes a “genomic” hit, or series of hits, 
causing oncogenic transformation. These stem cells are found at different stages of development; 
however they may likely give rise to a less differentiated tumor type, such as a basal or claudin-
low tumor.  
 Alternatively, an oncogenic hit can occur within a well-defined, mature luminal cell, 
resulting in a HER2-enriched or luminal tumor type (Visvader, 2009; Visvader and Stingl, 2014). 
As an attempt to exploit the relationship between mammary development and the intrinsic 
subtypes, Lim et al. (2009) sought to answer two key questions. First, they wanted to determine 
if they could isolate and characterize human mammary cells from reduction mammoplasties 
using two markers: EpCAM and CD49f. Each of the four populations—EpCAM-/CD49f-, 
EpCAM-/CD49f+, EpCAM+/CD49f+, and EpCAM+/CD49f-—represents the stromal, MaSC, 
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progenitor, and luminal fractions, respectively. The subpopulations were introduced into NOD-
SCID mice to determine their mammary regenerative capacity.  
 The EpCAM-/CD49f+, MaSC population was determined to have such capacity (Lim et 
al., 2009). Furthermore, each of the sorted fractions were characterized by various basal and 
luminal markers. The EpCAM-/CD49f+ MaSC group exhibited expression of KRT14, p63, and 
Vimentin—all basal markers—while the progenitor group, EpCAM+/CD49f+, expressed KRTs 
5/6, 8/18, 19, GATA3, and MUC1. As expected, the MaSC group lacked hormone receptor 
expression. The mature luminal group, EpCAM+/CD49-, stained positive for KRTs 8/18, 19, 
GATA3, and MUC1, although at higher frequencies than the progenitor. Hormone receptor 
detection of ESR1 and PGR was highest in the EpCAM+/CD49f- group, indicating this is the 
mature luminal population.  
 In terms of mammary development, membrane markers EpCAM and CD49f also 
segregate the mouse mammary hierarchy of development similarly, which is important to know, 
as the genomic classification of human breast EpCAM and CD49f subpopulations discovered in 
the Lim et al. (2009) study will be used to extrapolate the differentiation status of various mouse 
models in Chapter 2 (Shehata et al., 2012). There are other aspects of development in both 
species that appear to be conserved. For example, hormone expression is lacking in the EpCAM-
/CD49f+ MaSC subpopulation. The MaSC subpopulation expresses KRTs 5/6, p63, and EGFR 
while there is no expression of ERBB2/HER2, all of which are characteristics of the basal-like 
tumors (Bertucci et al., 2012; Kreike et al., 2007). However, the MaSC genomic signature was 
most enriched in both normal mammary and claudin-low tumors. This is likely due to the low 
proliferative profile and mesenchymal-associated genes found in both tissue types 
(Herschkowitz, 2007).  
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 The progenitor subpopulation contains both basal and luminal features; yet this group 
was found to have the greatest enrichment in the basal-like tumors, including the expression of 
ESR1 in a small subset of cells (Asselin-Labat et al., 2010; Nielsen, 2004). This may explain 
why approximately 10%–15% of basal-like tumors are ESR1 positive (Nielsen, 2004). It has 
been established that BRCA1 mutant breast tumors in both mouse and human are basal-like, 
which makes for a good model in understanding the origin of basal-like tumors (Akslen et al., 
2003; Liu, 2008; Turner et al., 2006). The study of the origin of BRCA1 tumors may be best 
studied in human subjects with germline BRCA1 mutations. Lim et al. (2009) compared the 
EpCAM and CD49f subpopulations in both BRCA1 wild-type and mutant normal breast samples 
from reduction mammoplasties. Curiously, the BRCA1-mutant normal progenitor fraction 
expanded significantly more than the matched BRCA1 wild-type group. Moreover, the growth 
properties of the mutant fraction were significantly greater than that of the wild-type group in 
vitro, confirming the consequences of BRCA1 loss in regulating cell cycle checkpoints (Lim et 
al., 2009).  
 Finally, the mature luminal subpopulation, EpCAM+/CD49f-, described in the Lim et al. 
(2009) study as ESR1, PGR, and KRTs 8/18 positive, are also found to be highly enriched in 
luminal A, luminal B, and HER2-enriched tumor types. To further characterize the functional 
aspects of this population, there was lack of growth in a 3-D Matrigel assay, a typical growth 
pattern seen in differentiated, quiescent cells, in the absence of lactogenic hormone stimulus 
(Gordon et al., 2000).  
 A more recent characterization of human breast cancer cell lines and normal mammary 
tissue was performed to identify their genomic correlation with one of the five intrinsic subtypes 
(Prat et al., 2013). Breast cancer cell lines have afforded the scientific community a valuable 
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resource for understanding the molecular mechanisms behind diseases and have given us an 
ability to effectively study the effectiveness and potency of drugs. While there are no luminal A 
models of breast cancer, MCF-7, a luminal B cell line, has allowed the elucidation of ESR1 
signaling through study of the effects of tamoxifen, an ESR1 antagonist. A reason for the lack of 
luminal A cell lines is that they are slow-growing tumors and are extremely difficult to propagate 
in culture. Basal cell lines such as SUM149 and HCC1143 have demonstrated expression of dual 
populations of MaSC (EpCAM-) and progenitor (EpCAM+) subpopulations.  
 These results have highlighted others’ work confirming that basal-like tumors may, in 
fact, exhibit both MaSC and progenitor phenotypes and growth characteristics (Liu, 2008; Prat et 
al., 2013). More importantly, these data have helped adopt the theory as to why basal tumors 
initially respond well to chemotherapy and then relapse, as such subpopulations are slower 
cycling and resistant to chemotherapy (Bertucci et al., 2012; Fillmore and Kuperwasser, 2008). 
The claudin-low tumors and normal mammary cell lines were classified in the Prat et al. (2013) 
study as representing the MaSC subpopulation, as these cell types are EpCAM-, express 
mesenchymal genes, and are slower cycling than their progenitor/basal EpCAM+ counterparts 
(Prat et al., 2013). These data and others confirm that the current repertoire of human breast 
normal and cancer cell lines recapitulate all of the hierarchical states seen in breast tumors, with 
the exception of luminal A tumors (Kenny et al., 2007; Neve et al., 2006; Prat et al., 2013; Prat et 
al., 2010). Figure 1.5 illustrates a summary of commonly used normal and cancerous cell lines 
and their respective locations along the developmental axis of differentiation.  
 The ability to transform breast cancer cell lines and tumor data into a format that 
represents their developmental status is crucial for interrogating the origin of the tumor. These 
data also represent the relative conservation of mammary development between mouse and 
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human, stressing the importance of reliably using mouse models in interpreting normal and 
oncogenic events in humans. The knowledge regarding where tumors are derived from yields 
valuable insight into how developmental cues can influence the characteristics of a tumor, 
including its response to therapy and metastatic potential. In addition, these studies have shown 
that the cell lines characterized closely resemble the tumors/normal tissue they are derived from, 
reinforcing their vital roles as reliable models for research. A critical issue that remains, 
however, is the lack of a cell line that represents the most commonly diagnosed breast cancer 
subtype, luminal A. Laboratories, including our own, are trying to utilize innovative ways to 
develop a working luminal A cell line for in vitro use. Some of these technical advances include 
the reprogramming of cells from one type to another, and such techniques have demonstrated 
success in a limited number of tissue types.  
1.3 Reprogramming/Transdifferentiation: What Has History Taught Us? 
 Cellular reprogramming, by definition, is the conversion from a somatic cell, such as a 
fibroblast, to a pluripotent stem cell (iPSC) by a number of mechanisms addressed in this 
section. The world went wild in 1996 when a laboratory at the Roslin Institute teamed up with a 
small biotech firm to create the first cloned animal, Dolly the Sheep. Ian Wilmut and colleagues 
transferred the nuclei of cultured epithelial cells into enucleated oocytes to create Dolly, who, 
ironically, lived a short 6 years (Edwards, 2010). The key to mammalian cloning success, 
scientists discovered, was the presence of nuclear factors. Such nuclear factors present within the 
nucleus blocked the effective transfer of genetic information; hence unfertilized meiotic stage II 
nuclei, where the nuclear factors reside in the cytoplasm, were used (Eggan et al., 2007). The 
question still remains, however, whether it can be utilized in human cells, as the successful 
reprogramming of human somatic cells has only been performed up to the blastocyst stage.  
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 The discovery and isolation of mouse embryonic stem cells (mESCs) in the early 1980s, 
followed by the establishment of human embryonic stem cells (hESCs) in the 1990s by James 
Thomson at the University of Wisconsin, were incredible breakthroughs not only for 
understanding the concept of pluripotency but also as a tool to manipulate cells into different 
lineages. Expanding on the nuclear transfer methods mentioned earlier, scientists discovered that 
transferring mESCs into a blastocyst, implanting it in vivo, and subsequently breeding can create 
mice entirely from the ESC DNA fingerprint (Graf, 2011). Basic biological tools used in the lab 
have been fine-tuned and designed to assist with reprogramming to pluripotency. The use of 
growth factors was found to be essential for many specialized cell types.  
 Cytokines, in particular LIF, were found to be essential for ESC growth and maintenance 
(Williams et al., 1988). RNA tumor viruses were later found to be an indispensable tool for the 
insertion of genes into a host genome at high efficiencies (Yu et al., 2007). Retroviral gene 
transduction was instrumental in the first positive iPS studies as a way to introduce and 
overexpress ectopic genes essential for reprogramming (Graf, 2011; Stadtfeld and Hochedlinger, 
2010; Takahashi and Yamanaka, 2006). Finally, it is worth mentioning that the creation of 
transgenic knock-in/out mouse models utilized in performing lineage-tracing experiments. The 
creation of a mouse line with a reporter construct inserted into Fbx15, a locus specific for ESC, 
was important for the discovery of iPSC reprogramming. Takahashi and colleagues used this line 
to select for Fbx15-positive cells, thus enriching for the propagation of iPS colonies in vitro 
(Takahashi and Yamanaka, 2006).  
 Takahashi and Yamanaka (2006) discovered the replacement of nuclear transfer lies in 
the ectopic overexpression of 4 transcription factors (OCT4, KLF4, SOX2, MYC) in a somatic 
fibroblast cell line. As a matter of fact, conversion of a somatic cell to an iPS cell was completed 
 
 
29 
in vitro, although the conversion is not always a complete one and has extremely low efficiency 
(< 1% of cells). Confirmation of the function of candidate iPS colonies was determined in two 
ways. First, colonies were transplanted into NOD-SCID mice and gave rise to all three lineages. 
Secondly, transfer of GFP-labeled iPS cells into a blastocyst resulted in embryos positive for 
GFP. After the pups were born, GFP-labeled cells gave rise to all three lineages, confirming that 
the induction of the four transcription factors in a somatic cell can create cells with pluripotent 
capabilities (Takahashi and Yamanaka, 2006).  
 Meanwhile, at the University of Wisconsin, James Thomson and colleagues created an 
OCT4 knock-in hESC cell line to screen for combinations of genes that could reprogram the cell 
line. Candidate colonies with transcription factors OCT4, SOX2, NANOG, and LIN28 that grew 
in geneticin (a selection marker on OCT4 promoter plasmid) were transplanted into NOD-SCID 
mice to demonstrate teratoma formation with all three lineages. Yu et al. (2007) also discovered 
that the iPS cells were demethylated at the OCT4 locus compared to controls, an epigenetic 
feature of embryonic stem cells. Both labs utilized similar mechanisms to demonstrate the 
feasibility of creating a functional iPS cell. The subtle differences in transcription factor selection 
were largely due to the species differences (mouse vs. human).  
 While their studies set off a wave of new research directions, limitations to 
reprogramming still persist. The low efficiency of conversion is a consequence of a couple of 
key technical and biological issues. Cellular transduction of all four transcription factors in every 
cell can be challenging as well. Choosing the most optimal viral delivery system is extremely 
important. Retroviral transgenes can be silenced toward the end of reprogramming due to 
methyltransferase activation, resulting in an incomplete repertoire of reprogrammed cells 
(Sridharan et al., 2009; Takahashi and Yamanaka, 2006). Lentiviruses are less likely to be 
 
 
30 
silenced than retroviruses; however, their constitutive activation can result in difficulties 
inducing differentiation of the iPS cell (Brambrink et al., 2008). A way to circumvent this issue 
is the creation of an inducible system, where induction/silencing of transcription factors can be 
controlled by the use of doxycycline. Moreover, reprogramming has been accomplished more 
recently without the use of viral vectors. Both human and mouse iPSCs have been derived by the 
delivery of recombinant proteins and whole-cell extracts isolated from ESCs, although the 
efficiency of this process is extremely low (Cho et al., 2010; Zhou et al., 2009). In order to 
overcome reprogramming inefficiencies, recent efforts have included the use of chemical 
compounds as another nonintegrating approach to iPSC development. While these agents, 
including histone deacetylase inhibitor valproic acid, increased reprogramming efficiencies, they 
have not been successful at replacing reprogramming factors (Desponts and Ding, 2010). 
Unlike the single iPS reprogramming experiment that occurred in 2006, the discovery of 
converting one cell type into another occurred in increments that started from the directed 
differentiation of fibroblasts into muscle cells by Myod, followed by the demonstration that 
committed and fully differentiated cells can be switched within the hematopoietic system and 
then finding that cell types from different germ layers could be interconverted (Davis et al., 
1987; Graf and Frampton, 1995; Huang et al., 2011). Many of these conversions were purposely 
sought out for therapeutic reasons: for example, b-islet cell production to alleviate 
hyperglycemia caused by insulin deficiency and cardiomyocytes from fibroblasts in heart injury 
(Ubil et al., 2014; Melton et al., 2008). These studies also demonstrate that the phenotype of the 
new transdifferentiated cells might not be identical to that of their “normal” counterparts. While 
this may be the case, their confirmed function in vivo raises hopes that specific transcription 
factor perturbations can be harnessed to generate therapeutically useful cells.  
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Some of the key transdifferentiation studies mentioned earlier relied on mouse embryonic 
fibroblasts (MEFs) as the host cell line. These cells are considered to be genomically stable due 
to nonconforming chromatin configurations and DNA modifications, among other attributes that 
can make working with MEFs both advantageous and troublesome (Vierbuchen and Wernig, 
2012). In 2011, Huang and colleagues published data on the successful conversion of mouse 
fibroblasts into functional hepatocytes. One consideration when starting with a primary cell line 
is its proliferative limitations. Alternatively, the generation of immortalized mouse fibroblasts 
has become an invaluable tool in studying transdifferentiation, although it depends greatly on the 
method of immortalization, as some can create genetic instabilities and become tumorigenic 
(Muhammad and Mohammad, 2013; Oh et al., 2007). MEFs derived from cdkn2a-null mice tend 
to be used due to their genetic stability despite continuous cycles of proliferation (Ieda et al., 
2010). Both the primary tail-tipped fibroblasts (TTF) and the cdkn2a-/- MEFs used in the Huang 
study were transdifferentiated with three defined transcription factors important for liver function 
(FOXA2, HNF1α, and GATA4). Conversion into induced hepatocytes (iHEP) took 2–3 weeks, 
and while there was no selection based on a tagged reporter as seen in the iPS studies, 
“candidate” colonies were selected based on morphology and expression of key epithelial 
markers. Production of key liver enzymes was confirmed, and ultimately the test for true 
functionality came when the iHEP cells were injected into Fah-/- mice (a mouse strain with 
severe liver disease that ultimately causes liver failure and death). The iHEP cells were 
transplanted into this strain, resulting in over 80% survival rate after 60 days, while the control 
group were all dead within that time frame (Huang et al., 2011). The Huang study, as well as 
others, exhibited a decrease in exogenous expression of defined TFs, suggesting that despite the 
conversion, the unremitting overexpression was not necessary. These induced cells may not 
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express and/or produce proteins at the same level as their tissue counterparts, despite the fact 
they function similarly in vivo (Vierbuchen et al., 2010; Virmani et al., 2001). Finally, the 
conversion of cdkn2a-/- MEFs does not seem to promote tumor growth, suggesting that silencing 
a key component of the cellular senescence pathway does not increase risk of transformation. 
Transdifferentiation studies have been successfully executed across several tissue types. Similar 
to iPS, conversion events are rare and colony selection is critical, as conversion includes several 
intermediate stages comprising heterogeneous cells. Other considerations going forward include 
understanding the role of chromatin modifications and how they affect the rate or completion of 
cellular conversion. Besides the established technical limitations, it is crucial to understand why 
conversion so rare. Is there an underlying biological process that can explain this? Moreover, the 
creation of an induced cell line representing reproductive tissue and utilizing viral transduction 
methods has yet to have been achieved.  
 One approach in developing a functional prostate gland was tested several years ago with 
tissue recombination. Mesenchymal cues are necessary for the development of reproductive 
organs, including the prostate, uterus, and breast. Taylor et al. (2006) sought to create a 
functional prostate by combining spermatogonial stem cells (SSC), which are pluripotent, like 
human ESCs, with cells of mesenchymal origin—urogenital sinus mesenchyme (USM). Cells 
from the USM give rise to either prostate cells in males or uterine tissue in females, and early 
studies on the importance of mesenchyme dictating epithelial fate have been established (Cairns 
and Saunders, 1954). Ultimately, the process of tissue recombination resulted in the development 
of prostate tissue that expressed prostate-specific antigen (PSA), and expressed basal and luminal 
markers associated with the cellular organization of the prostate gland. The process of mature 
glandular development took 8–12 weeks, highlighting the arduous amount of time needed for 
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development, a stark contrast to the 3–4 week time frame for iPS conversion (Takahashi and 
Yamanaka, 2006; Taylor et al., 2006).  
 Mammary tissue, similar to prostate tissue, develops slowly relative to other organs. It is 
reliant on hormonal signaling cues from distant organs, as well as local mesenchyme (Cooke et 
al., 2010; Tanos et al., 2012). The origin of the mammary epithelial cell is poorly understood. 
The complicating factors include the time for reaching maturity, which in humans is not until 
puberty. It is therefore possible that well-controlled epigenetic mechanisms maintain the 
quiescence of the gland until puberty/pregnancy is reached. The ability of such mechanisms to 
successfully keep cells in check for years in humans may explain the difficulties in creating a 
mature luminal breast cell line. The next few chapters will discuss attempts to create a luminal 
breast line, as well as the study of a key pioneer factor that may be crucial in reversing the 
epigenetic regulation of breast stem cells, GATA3.  
1.4 Summary 
 Mammary development requires stepwise changes in tissue interaction, hormones/growth 
factors, and tightly regulated transcription. Breast cancers appear to reflect the molecular aspects 
of the stage at breast differentiation from which they arise. Luminal A tumors appear to be the 
most differentiated and slowest growing; currently, there are no models for luminal A tumors. 
Finally, there is literature describing the utility of transdifferentiation from one somatic cell type 
to another, which has been largely successful due to the sentinel work in the development of iPS 
cells.   
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Table 1.1. Current Mammary Mouse Models and their Phenotypes 
 
Note. NA = not applicable, or not described. 
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Table 1.2. Mammary Specific Lineage Markers Commonly Used in Mice 
 Fibroblast
s 
MaSC Basal  
Progenitor 
Luminal 
Progenitor 
Luminal 
EpCAM - - + ++ +++ 
CD49f - +++ ++ ++ -/+ 
ALDH-1 ++ ++ - -/+ - 
SCA-1 ++ - - -/+ + 
c-KIT ++ - + ++ - 
CD14 - - -/+ ++ - 
CD49b ++ - ? -/+ - 
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Figure 1.1. Embryonic Mammary Gland Development 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Christine J. Watson and Walid T. Khaled, “Mammary Development in the 
Embryo and Adult: A Journey of Morphogenesis and Commitment,” 2008, Development 135(6): 
995-1003. Reproduced with permission. 
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Figure 1.2. Mammary Ductal Network from a 20 Week Old Mouse 
 
Note. Close-up of terminal end bud (TEB) with lumen marked with L. Luminal cells are body 
cells, and stained red, while basal cells (cap cells) are stained green. The surrounding stroma is 
stained brown and consists of adipocytes. 40x magnification. 
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Figure 1.3. The IL4/13-STAT6-GATA-3 Pathway in Mammary Gland Development 
 
 
 
Adapted from Christine J. Watson and Walid T. Khaled, “Mammary Development in the 
Embryo and Adult: A Journey of Morphogenesis and Commitment,” 2008, Development 135(6): 
995-1003. 
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Figure 1.4. Differentiation Hierarchy for Mouse Mammary Development 
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Figure 1.5. Human Breast Cancer/Normal Cell Line Alignment along a Differentiation Axis 
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CHAPTER 2: SPECIFIC COMBINATIONS OF TRANSCRIPTION FACTORS  
INDUCE TRANSDIFFERENTIATION TO A MAMMARY LUMINAL  
EPITHELIAL CELL PHENOTYPE1 
Introduction 
Luminal A tumors, one of 5 intrinsic subtypes originally defined by Perou et al., account 
for roughly 40% of all breast tumors diagnosed (Prat et al., 2010). Patients with luminal A 
tumors have a favorable prognosis compared to the other intrinsic subtypes, with a 10-year 
relapse free survival rate of 70% (Koboldt et al., 2012). However, the 30% relapse rates indicate 
that additional knowledge and better treatment are still needed. Typically, treatment consists 
primarily of surgical resection and estrogen-modulating therapy. Radiation and chemotherapy 
are also considered depending on location, lymph node involvement, tumor size, and/or 
OncoTypeDX intermediate/high recurrence score. While these patients experience superior 
overall and disease-free survival compared to patients with luminal B, basal, HER2 positive, 
claudin-low tumors, they do have a risk for relapse. Studies that directly evaluated the response 
to neo-adjuvant chemotherapy across the subtypes have shown that luminal A tumors achieved a 
pathological complete response (pCR) of 7%, versus a pCR of 43%, 36%, and 17% for basal, 
HER2-enriched, and luminal B tumors, respectively (Keller et al., 2010). These and other studies 
have highlighted the significant differences in chemotherapeutic sensitivities between luminal 
(predominantly ER+) and basal (predominantly ER-) tumors. There have been several attempts 
                                                          
1 Francesca G. Bargiacchi, Joel Parker, Charles M. Perou, and H. Shelton Earp, “Specific 
Combinations of Transcription Factors Induce Transdifferentiation to a Mammary Luminal 
Epithelial Cell Phenotype,” rest of journal info. 
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to explain this difference. Luminal A tumors are clinically classified as ER+, HER2-, and ki67-
low, suggesting that slow cycling may cause these tumors to be relatively insensitive to 
chemotherapy (Inic et al., 2014). Because these patient tumors are slowly proliferating, in vitro 
propagation has been largely unsuccessful. In addition, there are no luminal A mouse models due 
to a lack of hormone dependency in murine mammary development.  
Unlike the pivotal iPS reprogramming experiments reported 8 years ago, the discovery of 
approaches to directly convert one differentiated cell type into another has occurred 
incrementally, starting with the directed differentiation of fibroblasts into muscle cells by Myod 
(Davis et al., 1987). Later came the demonstration that committed and fully differentiated cells 
can be switched within the hematopoietic system and more recently the finding that cell types 
from different germ layers can be interconverted. For example, laboratories have recently 
published the successful transdifferentiation of fibroblasts into functional neurons and liver cells 
(Vierbuchen et al., 2010; Huang et al., 2011). While these studies showed that the phenotype of 
the new transdifferentiated cells might not be entirely identical to that of their “normal” 
counterparts, the fact that they acquire critical cell-type specific functions in vivo raises hopes 
that defined transcription factor perturbations can be harnessed to generate useful cells for both 
research and clinical purposes.  
Currently, the understanding of genetic reprogramming in breast cancer has largely been 
limited to two main areas. Studies have demonstrated that pre-neoplastic/breast cancer cell lines 
can be reprogrammed in a paracrine fashion via the stromal environment (Bussard et al., 2010; 
Verbeke et al., 2014). Secondly, breast cancer cells can be partially reprogrammed to a more 
“plastic” state via direct introduction of defined transcription factors. A key study introduced the 
4 defined transcription factors identified in Yamanaka’s pivotal iPS work—Oct4, Sox2, Klf4, 
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and c-Myc (OSKM)—into MCF-7 cells, a human luminal breast cancer cell line (Corominas-
Faja et al., 2013). While the MCF-7 cells did not adopt an iPS functional phenotype, they 
exhibited some stem cell characteristics, such as ES organoid formation in Matrigel and 
expression of stem cell markers ALDH and CD44 (Corominas-Faja et al., 2013). Similar studies 
have introduced TGF-β and/or downstream SMAD family TFs to induce cancer “stemness” from 
normal mammary epithelia (Piek et al., 1999). However, there are few, if any, studies attempting 
to transdifferentiate breast epithelial cells either from more stem-like cell types or from cells 
representing other lineages. It is likely that fully differentiated breast cells may represent a 
quiescent state or even be committed to senescence or cell death under some circumstances. This 
could create a serious roadblock to creating model systems. Other considerations for 
transdifferentiation strategies include host cell and/or genes used for direct reprogramming. 
Yamanaka’s iPS experiments were successfully executed using somatic fibroblasts (Takahashi 
and Yamanaka, 2006). However, the transcription factors used (OSKM) are also involved in 
epigenetic events that influence chromatin modifications and alterations in the methylation of 
DNA, which contribute to the formation of iPS cells (Patel and Yang, 2010). Hence, methylation 
is a concern when starting with a lineage-committed cell line, and the selection of transcription 
factors with chromatin modification abilities and/or methyltransferase inhibitors may represent 
strategies to circumvent this. 
In the present study, the selection of transcription factors for breast luminal cell 
reprogramming was predicated on their enrichment in luminal A human tumors as compared to 
all other intrinsic subtypes. For this analysis, we used the preexisting UNC337 data set, which 
has been extensively studied and subtyped. We chose the following nine candidate transcription 
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factors with known relevance to breast biology: AR, DACH1, ESR1, FOXA1, GATA3, LEF1, 
MYB, PGR, and XBP1. 
Estrogen receptor alpha (ESR1) and progesterone receptor (PGR) are used clinically to 
define hormone-positive breast cancer (Parker et al., 2009). FOXA1, a pioneering factor, has 
been shown to been an indispensable partner for ESR1 and PGR signaling (Hurtado et al., 2011). 
FOXA1 can effectively bind chromatin domains during development and enable gene activity. 
The FOXA1-DNA binding domain structurally resembles linker histones and can bind 
nucleosomes, thus influencing the accessibility of certain transcription factors to their binding 
sites on particular promoters (Gong et al., 2014). Utilizing two different cell types, first BABES, 
an hTERT-immortalized human mammary epithelial cell line, and later mouse embryonic 
fibroblasts (MEFS), immortalized via the knockout of cdkn2a, we set out to determine if the 
creation of a luminal-like breast cell line would be feasible in either cell line. These two lines 
represent different lineages and begin with different methylation patterns (Bloushtain-Qimron et 
al., 2008; Doi et al., 2009). Experiments with the human BABE cell line led to a hypo 
proliferating and senescent population. Subsequently, we discovered that 3 of the 9 genes 
tested—ESR1, FOXA1, and PGR—can transdifferentiate MEFS into functional epithelial cells 
with breast luminal and basal characteristics. These findings shed light on the necessary 
molecular mechanisms for normal breast development and those that perhaps underlie the 
various intrinsic subtypes of breast cancers. 
2.1 Materials and Methods 
2.1.1 Plasmids 
All gene ORFs were purchased in a pDONR223 entry vector (Harvard/Dana Farber 
Human ORFeome 5.1). Lentiviral destination vectors pLenti-PGK-hygro-DEST, pLenti-PGK-
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blast-DEST, pLenti-PGK-neo-DEST, and pLenti-PGK-puro-DEST were used as the mammalian 
expression vectors (http://www.addgene.org). pLENTI-PGK-GFP-blast and the pLENTI-PGK-
DEST backbones were used as positive/negative transduction controls. Final lentiviral 
expression plasmids were created using Invitrogen’s recommended protocol for the Gateway 
system. Plasmids were then sequenced to verify ORF insertion and sequence. 
2.1.2 Virus Production 
293FT cells (Invitrogen, Life Technologies) were cultured in high-glucose DMEM 
(Gibco, Life Technologies) with 10% fetal bovine serum (FBS), 500 μg/ml Geneticin®, 1 mM 
MEM Sodium Pyruvate, 0.1 mM MEM Non-Essential Amino Acids (NEAA), 6 mM L-
glutamine, and 1% Pen-Strep up until the day before transfection. Then they were switched to 
the same media without Geneticin. On the day of transfection, in one tube, 3ug of either one of 
four pLENTI-PGK backbone plasmids was added to 9ug (9ul) Virapower (Invitrogen, Life 
Technologies) in 1.5 mls of Optimem media (Gibco, Life Technologies). This was performed for 
each of the 9 genes, the GFP, and the negative control plasmids (backbones only). In a separate 
tube, 36ul of Lipofectamine2000 (Invitrogen, Life Technologies) was added to 1.5 mls Optimem 
media. Both tubes sat for 5 min at room temp and then were mixed together and incubated at 
room temp for an additional 20 min. Each 10 cm dish of 293FT cells received 5 mls of DMEM 
growth media plus 3 mls of the plasmid-lipofectamine2000 mixture. Cells were incubated at 37 
°C for 24 hours. Then the media were switched out for 10 mls fresh DMEM growth media for 
another 24 hours. The media were then collected, passed through a .2 um filter, and stored at –80 
°C. 
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2.1.3 Cell Culture 
The BABE cell line (hTERT-immortalized human mammary epithelial cells from the 
Counter lab, Durham, NC) was maintained at 37 °C in HuMEC medium supplemented with 
bovine pituitary extract, supplements, and 1% Pen-Strep (Troester, 2004). Embryonic fibroblasts 
from cdkn2a-/- C57BL/6 mice were maintained at 37 °C in RPMI medium (Gibco, Life 
Technologies) with 10% FBS and 1% Pen-Strep (kindly donated to us by the Sharpless Lab, 
UNC-Chapel Hill). For the 4-day proliferation studies, cells were treated with either a range of 
tamoxifen (Sigma) or 17β-estradiol (Sigma). For the prolactin (Sigma) and combination 17β-
estradiol and progesterone 4-day treatments, 100ng/ml, 10ng/ml, and 100nM of each were used, 
respectively. 
2.1.4 Generation of Stable Cell Lines 
BABE cells were plated into 6-well plates at a seeding density of 100,000 per well. 
Lentiviral infections were performed with 500 ul single virus plus 8 ug/ml polybrene in 2 mls 
HuMEC media with supplements (no antibiotics), as described above. For the combination 
viruses (1 ml of pooled virus) was added to 1 ml HuMEC media for a final volume of 2 mls. 
Cells were incubated at 37 °C for 24 hours. The media were changed to HuMEC with 
supplements for another 24 hours. Finally, selection media were added (HuMEC plus 
supplements) with one of the following antibiotics, depending on the pLenti-PGK- backbones. 
For puromycin, 1 ug/ml, 400 ug/ml Geneticin®, 200 ug/ml hygromycin, and 2 ug/ml blasticidin 
were in media for 2 weeks. Cdkn2a-/- MEFS were plated in 6-well plates at a seeding density of 
100,000 per well. Combination viruses totaled 1 ml and were added to 1 ml RPMI plus 10% FBS 
and 8 ug/ml polybrene. For GFP and negative control viruses, 500 ul were used. Cells were 
incubated at 37 °C for 24 hours. The media were changed to RPMI plus 10% FBS for 48 hours. 
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Cells were then serum starved and placed in HuMEC media plus supplements. Both cell lines 
were tested and confirmed for gene expression by quantitative PCR over several time points 
(data not shown). 
2.1.5 RNA Isolation and cDNA Synthesis 
Cells were grown to about 80% confluency, trypsinized, and washed twice with PBS 
(Gibco, Life Technologies) before isolating the total RNA with the Qiagen RNeasy kit (Qiagen). 
The RNA was quantified using the Nanodrop (ThermoFisher), and 1ug of RNA was made into 
cDNA with the iScript kit (BioRad). 
2.1.6 Quantitative PCR  
For each of the following human gene targets (AR, DACH1, ESR1, FOXA1, GATA3, 
LEF1, MYB, PR, and XBP1), forward and reverse primer mixes were purchased from Origene. 
The primer sequences for murine genes KRT14, CDH1, PRLR, Vimentin, COL1A2 are listed 
here in order: KRT14-F: GAAGAACCGCAAGGATGCTGAG, KRT14-
R:TGCAGCTCGATCTCCAGGTTCT. CDH1-F: GCTGTTGTGCTCAAGCCTTCAC, CDH1-
R: CGGAAAGTGGAATCCTTGCAG. PRLR-F: GCATGATGACCTGCATCTTTCC, PRLR-
R: CAAGGCACTCAGCAGTTCTTCT. VIM-F: AGCAGTGAGGTCAGGCTTGGAA, VIM-
R: AGCAGTGAGGTCAGGCTTGGAA. COL1A2-F: TTCTGTGGGTCCTGCTGGGAAA, 
COL1A2-R: TTGTCACCTCGGATGCCTTGAG. TATA Box Binding Protein (TBP) was used 
as the endogenous control. TBP-F: CTACCGTGAATCTTGGCTGTAAAC, TBP-R: 
AATCAACGCAGTTGTCCGTGGC. Taqman SYBR Green Master Mix (ABI, 
LifeTechnologies), 20ng of cDNA, and a final primer concentration of 200nM were used and run 
on the ABI 7900 (ABI, Life Technologies). Relative concentrations were first normalized to 
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TBP. Then relative fold changes were calculated using either parental BABE or MEF as the 
control. Samples were run in triplicate. 
2.1.7 Western Blotting 
Cells were lysed in RIPA buffer containing 50 mM TRIS HCL, pH 8, 150 nM NaCl, 1 
mM EDTA, 1% NP-40, 0.25% deoxycholate, and 30ug of protein were separated on SDS-
PAGE. Primary antibodies were used at a dilution of 1:1000, and secondary antibodies were used 
for two-color fluorescent detection at a dilution of 1:5000 for rabbit (680) and 1:10,000 for 
mouse (800). Analysis was conducted with the LI-COR Odyssey system (LI-COR Biosciences).  
2.1.8 Proliferation Assays/IC50 Curve Analysis 
BABE cells and their respective single transductants were seeded at a density of 5 x 103 
per well in a 96-well plate for 4 d. MEF and M-EFP cells were seeded at a density of 3 x 103 per 
well in a 96-well plate for 4 d. The MEF experiments included a treatment of either β-estradiol 
10 uM–1 pM) or tamoxifen (10 uM–1 nM) in a dose response fashion. Next, 20 ul of 
CellTiter96® Aqueous One Solution cell proliferation assay solution (Promega) was added to 
each well and incubated at 37 °C for 2 hours. Then its absorbance was measured at 490 nm on a 
spectrophotometer (Molecular Probes). Four to 6 replicates for each cell line/condition were 
measured. This was repeated twice. We calculated the IC50 by calculating the nonlinear 
regression, sigmoidal dose-response, 3-parameter curve fit in GraphPad (GraphPad Software, 
Inc.). At least 5 replicates were used for each dose. Each experiment was repeated 2–3 times. 
The data shown include mean and SD values.  
2.1.9 Flow Cytometry 
Cells were grown to 80% confluency, trypsinized, counted, washed with HBSS (Gibco, 
Life Technologies) plus 2% FBS (HF), blocked in goat serum for 10 min at 4 °C, and stained for 
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30 min at 4 °C with the following antibodies at a 1:100 dilution: CD61-FITC (Biolegend), 
CD29-APC (Biolegend), CD24-PE (BD Biosciences), and EdU-FITC (Invitrogen, Life 
Technologies). Finally, cells were fixed in 2% PFA for 30 min, washed 2X with HF, and 
analyzed using Beckman-Coulter Cyan (Dako). The data were analyzed and compensated using 
FlowJo X (FlowJo, LLC). The FACS experiments were repeated twice.  
2.1.10 Immunofluorescence with and without Matrigel 
MEFS and M-EFP cells were plated on collagen-coated 8-well chamber slides at a 
density of 2 x 104 per well for 4 days at 37 °C. For cells on collagen-coated glass chamber slides, 
cells were fixed in 2% PFA, permeabilized with .5% triton X-100, and washed with PBST before 
blocking with 10% donkey serum in PBST. The secondary block used was the primary plus 13 
ug/ml mouse F(ab)2 (Jackson labs) in PBST. Primary antibodies were used at a 1/100 dilution 
and included CDH1 (Santa Cruz), Vimentin (Novus), PRLR (Santa Cruz), CSN2 (Santa Cruz), 
KRT18 (Abcam), KRT5 (BD Biosciences), and KI67 (Cell Signaling Technologies). Secondary 
antibodies used at a 1/200 dilution were Alexa dyes 488/594/647 (Molecular Probes, Life 
Technologies). DAPI stain was also purchased from Life Technologies and used at a 
concentration of 1 ug/ml. Cells were mounted with Prolong Anti-fade (Molecular Probes, Life 
Technologies). For Matrigel IF, 100 ul of low-growth Matrigel (BD Biosciences) was carefully 
placed in each well of an 8-well chamber slide and dried at 37 °C for 20 min. Next, 5 x 103 cells 
were plated for a total of 4 days in HuMEC media plus 2% low-growth Matrigel with the 
following supplements: 5% FBS, .5 mg/ml hydrocortisone, 10 ug/ml insulin, 100 ng/ml cholera 
toxin, 10 ng/ml prolactin, and 1% Pen-Strep. Cells in matrigel were processed as previously 
published (Debnath et al., 2003a), and antibodies, DAPI, and Prolong Anti-fade were used in the 
same manner as cells on glass slides (Debnath et al., 2003b). Images were taken on a Zeiss710 
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confocal microscope. Images were analyzed and median filtered on all samples to reduce minor 
background using ImageJ (freeware, http://imagej.nih.gov/ij/)  
2.1.11 Gene Expression Microarrays 
The human tumor and cell line microarray data set came from Prat el al. (UNC337, 
GSE18229) (Prat et al., 2010). The murine tumor data set is a subset of 385 gene expression 
microarrays from Pfefferle et al. (2013). Total RNA was purified from the BABE and MEF 
experimental samples using Qiagen’s RNeasy minikit following the manufacturer’s protocols. 
The RNA quantity was assessed using the Nanodrop spectrophotometer (ThermoFisher). Total 
RNA (1 ug starting input) was reverse transcribed and labeled with cyanine-5 (Cy5) dye for 
experimental samples and cyanine-3 (Cy3) dye for either human (BABES) or mouse (MEFS) 
reference samples using the Agilent Low RNA Input Fluorescent Linear Amplification Kit 
(Agilent). Equal quantities of either human or mouse reference RNA and experimental RNA 
were cohybridized overnight to either human 4 x 44k or mouse 4 x 180k Agilent microarrays, 
washed and scanned. Microarray intensity values were extracted as log
2 Cy5/Cy3 ratios. Probes 
were filtered with Lowess normalized intensity values greater than 10 in both channels and 
averaged by mapping probes to the same gene (Entrez ID). Finally, only probes with data in 
more than 70% of the arrays were used in the analysis (Herschkowitz et al., 2007; Prat et al., 
2010). 
2.1.12 Informatics Analysis 
GSA was performed using the R-script Arraytools (https://cran.r-project.org/). For the 
analysis, two biological and technical replicates were used for both the MEFS–ctrl and M–EFP 
microarray data. The set of transcriptional gene pathways used to define the enriched data set in 
M–EFP relative to MEFS–ctrl originated from the Molecular Signature Database (MSigDB), 
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which is a collection of gene sets maintained by the GSEA team (http://www.broadinstitute.org). 
The particular gene set we used to enrich for genes in the M–EFP cells was the C3 motif data set, 
transcription factor targets (TFT). The TFT is comprised of transcription factors and their 
downstream targets, as described previously (Xie et al., 2005). Differentially regulated TFTs (4) 
between MEFs and M–EFP were clustered using Treeview software.   
 For the differentiation score algorithm (d-score), human and mouse data sets were 
analyzed separately. Samples were scaled to mean zero and variance of 1. Features were then 
collapsed to the mean of each gene identifiers. Lim et al. (2009) generated gene expression 
profiles of three different epithelial cell-enriched subpopulations in breast: mammary stem cells 
(MaSC), luminal progenitors (pL), and mature luminal cells (mL). We used these as references 
to create a differentiation predictor for each sample as a measure of any sample’s position along 
a MaSC  pL mL axis as defined by gene expression. The axis was expressed as 2 vectors, MaSC    
pL and pL mL, where pL is transformed for 0, and each vector length is –1, 1, respectively. Data 
were then graphed either combining both axis or by values on each axis. ANOVA and unpaired t 
tests were used to determine significant differences between groups/samples.   
2.2 Results 
2.2.1 Transcription Factors Enriched in Luminal Tumor/Cell Lines 
 Nine transcription factors (see Table 2.1) were chosen based on several factors, including 
a literature review, previously published data from our lab, and SAM analysis (Significance 
Analysis Microarrays, Stanford University) performed on the UNC337 tumor data set, which 
comprised 320 breast tumors and 17 normal breast samples (GSE18229) (Prat et al., 2010). 
Tumors in the UNC337 tumor data set were first classified by their PAM50 status, as defined by 
Parker et al. (2009). SAM analysis was performed comparing the differential gene expression 
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patterns of luminal A primary tumors compared to all other tumor types (luminal B, HER2-
enriched, basal, claudin low) using a false discovery rate (FDR) of < 1%. To identify genes 
found enriched in the luminal A primary tumors that are also expressed in luminal B cell lines, 
we performed SAM analysis at a FDR of < 1% on a breast cancer cell line data set published 
previously (Neve et al., 2006). Selecting the genes in common with both luminal A tumors and 
luminal B cell lines, we then filtered the gene set based on gene function. We devised a list of 9 
transcription factors, which include (AR, DACH1, ESR1, FOXA1, GATA3, LEF1, MYB, PGR, 
and XBP1). The selected transcription factors have also been shown to have some role in luminal 
breast cellular pathophysiology (Perou et al., 2000; Prat et al., 2010, 2013). 
2.2.2 Stable Cell Lines Expressing Candidate Transcription Factors 
 In order to determine the optimal combination of genes for luminal cell reprogramming, 
we transduced the BABE cell line with the individual TF genes and assessed their differentiation 
potential via a differentiation predictor model using data from Lim et al. (2009). The model 
assumes that mammary differentiation starts from a mammary stem cell (MaSC) and develops in 
progression to a progenitor luminal phenotype (pL), with terminal differentiation as a mature 
luminal cell (mL). In this model, higher scores represent a higher degree of differentiation along 
either of the two axes (see Figure 2.1A). We applied this model to both the tumor and the cancer 
cell line data sets as a comparison of where breast cancer intrinsic subtype samples fall along the 
differentiation axis. The data were fit onto both axis (MaSC  pL, and pL  mL), to 
determine whether the degree of differentiation is moving sequentially in our linear model or 
skipping phenotypes (pL for example). The luminal tumors had the greatest shift along the pL 
 mL axis, which was expected since these are the most differentiated of the tumor subtypes. 
Basal tumors, on the other hand, have more movement along the MaSC  pL axis than the pL 
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 mL axis, though they are in the middle of the MaSC  pL axis largely due to heterogenous 
characteristics of basal tumors. The luminal B and HER2-enriched cell lines move much more 
closely along the MaSC  pL axis, likely due to the fact they are grown in culture and lose 
some mature luminal features such as a low proliferation rate, for example. The BABE cell line 
has been classified as basal by PAM50 and correlates with the basal cell lines on the MaSC  
pL axis. BABES stably transduced with individual TFs from our panel also move more along the 
MaSC  pL axis, with BABE-GATA3 moving significantly in the pL direction. BABE-ESR1 
moved the most along the pL  mL axis, making this a candidate gene for inclusion in the TF 
combinations to be tested in the next steps. Based on previous data suggesting that FOXA1 is 
critical for ESR1 function and response to 17β-estradiol (Hurtado et al., 2011), FOXA1 was also 
included in all of the combinations we tested. Two of the combinations shown, ESR1–FOXA1–
PGR (EFP), and ESR1–FOXA1–GATA3 (EFG) show the greatest movement along the pL  
mL axis, with EFG having a slightly higher mL score than EFP. Interestingly, BABE–PGR has a 
lower pL  mL score than the control BABE cell line BABE–GFP. Interestingly, BABE–
ESR1 and BABE–EFP are indistinguishable by level of movement towards the mL phenotype, 
which may suggest that FOXA1 and PGR do not influence changes along the pL  mL axis 
like they do individually along the MaSC  pL axis. 
2.2.3 ESR1 Expression in BABES Induces Cellular Senescence  
We observed that stably transduced cells expressing different TFs displayed markedly 
different growth rates while being maintained in culture. This was quantified by plating 
monolayers of each TF-induced cell line, including both the parental and GFP-transduced 
BABES, and measuring viable cells by MTS assay after 4 days at 37 °C (Figure 2.1B). BABES 
expressing ESR1 (p = .0001, unpaired t test, 2-tailed) or AR (p < .0001, unpaired t test, 2-tailed) 
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grew more slowly than the other cell lines. To corroborate these data, we replated the same 
groups and stained them with EdU, a BrdU analog, to assess cellular proliferation via DNA 
replication. BABE–ESR1 cells display extremely low proliferative activity compared to negative 
control cells (Figure 2.1C) or to BABE–FOXA1 or –PGR cells (data not shown). Notably, a 
triple-transduction protocol including FOXA1 and PGR failed to rescue the growth suppression 
induced by ESR1 and these BABE–EFP cells died off after about 2 weeks after viral infection. In 
order to elucidate the mechanism underlying cellular arrest in the BABE–ESR1 cells, we 
performed a 2-class unpaired SAM analysis comparing the differential expression of genes 
between BABE–GFP and BABE–ESR1. We then overlaid these data onto a Cytoscape 
(http://www.cytoscape.org/) cell cycle pathway map developed in our lab. As shown, genes 
involved in halting cell cycle progression (p53, RB, p15) are upregulated relative to the BABE–
GFP control group (Figure 2.1D). The alterations of cell cycle genes observed in BABE cells 
transduced with other TFs in our panel are also consistent with their cell count data (Figure 2.2). 
In addition, we performed a β-galactosidase assay to measure cellular senescence (data not 
shown), which confirmed the BABE–ESR1 cell lines were senescing relative to GFP control. 
Altogether these data showed that the BABE cell line was a difficult model with which to 
approach our objective of obtaining a transdifferentiated cell line with luminal A characteristics 
that could be propagated and studied in culture. Thus, it may not be an effective model for 
studying differentiation because of the inability to maintain the induced differentiated cells in 
culture. 
2.2.4 MEFS Transduced with EFP (M–EFP) Exhibit Epithelial Phenotype 
 Cdkn2a-/- MEFS were transduced and serum starved for 1 month (Figure 2.3A). Based on 
our earlier findings, we transduced MEFS with several gene combinations, focusing on ESR1, 
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FOXA1, GATA3, DACH1, XBP1, and PGR. In order to determine which combination to 
pursue, ectopic expression was first confirmed by qPCR. Then RNA was amplified, labeled, and 
run on Agilent microarrays. Morphologic changes began to develop after maintaining the 
transduced cells for approximately 3 weeks in culture. Gene expression patterns were analyzed 
using a variation of the differentiation predictor method, in which the MaSC  pL and the pL 
mL axes were combined into a single MaSC mL axis as a way to measure overall differentiation. 
We then used this compilation score (d-score) value to screen different combinations of 
transcription factors. MEFS were transduced as described in methods, and after 1 month, stable 
expression of ectopically introduced TFs was confirmed by qPCR (data not shown).  
Interestingly, while EFG produced the highest d-score shift in BABE cells (Figure 2.1A). 
This did not hold true when the combination was expressed in MEFS (Figure 2.3B). The EFP 
combination effect was more consistent between the two MEF cell lines, and so we initiated 
further studies with this combination. By 1 month, the M–EFP cells exhibited a uniform 
cobblestone pattern compared to the parental MEFS (Figure 2.3C). We analyzed protein levels of 
ESR1, FOXA1, and PGR on Day 30, as well as later passages (Figure 2.3B, data not shown), and 
the biological replicates maintain expression of the 3 proteins. In order to first assess whether the 
TFs produced a shift toward an epithelial phenotype, we performed qPCR on RNA prepared 
from MEFS and M–EFP after 1 month in culture to determine if there were expression losses in 
mesenchymal genes and/or gains in epithelial genes. As a screen, we chose 2 mesenchymal 
genes (Vimentin and COL1A2) and 2 epithelial genes (KRT14, a common basal breast marker, 
and CDH1). Both KRT14 and CDH1 were overexpressed relative to MEFS, while Vimentin and 
COL1A2 expression was decreased in M–EFP relative to MEFS (Figure 2.4A). This was 
confirmed by immunofluorescent detection of protein expression. M-EFP displayed positive 
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staining with CDH1 and KRT14, as well as pan-cytokeratin, while minimal or no staining for 
these proteins was observed in MEF control cells.  
Interestingly, while MEFS stain positively for Vimentin as it is a classic mesenchymal 
marker, immunostaining of Vimentin in M-EFP did not correspond with the decrease in 
Vimentin RNA seen in the qPCR results. The immunofluorescence panel also included ERBB3, 
a tyrosine kinase expressed predominately in epithelial tissues, as well as a marker for luminal 
epithelia in the breast (Balko et al., 2012). ERBB3 expression is positive in the M-EFP cell line, 
with both membrane and nuclear staining present as compared to MEFS. Finally, we stained both 
cell lines with phalloidin, and under 40x-oil magnification, to examine cytoskeletal F-actin 
arrangements. As shown in Figure 2.4D, there is a clear morphological difference between the 
parental MEF and M–EFP, as the M–EFP cells take on a cuboidal epithelial phenotype with 
cortical actin circumferentially located around the membrane. On the other hand, the MEF cells 
retain their classic stress fiber structure. 
2.2.5 M-EFP Cells Exhibit Expression of Breast Epithelial Markers 
Both MEF and M–EFP cell lines were cultured in low-growth Matrigel and in it have 
distinct growth patterns at 10x magnification (Figure 2.5A). MEFs grew as dispersed single cells 
exhibiting little cell–cell cohesion, whereas M–EGP formed distinct spherical colonies. Western 
blot analysis for KRT5 and 18, markers for breast basal and luminal cells, respectively, 
demonstrated KRT5/18 expression in M–EFP cells, while MEF had no KRT5/18 expression 
(Figure 2.5B). To determine the localization pattern of KRT 5/18, we performed 
immunofluorescence staining of the cells in low-growth Matrigel for both keratins and found the 
M–EFP cells to be positive for both, with a concentration of KRT18 around the periphery of the 
spherical colonies (Figure 2.5C). Thus, M–EFP cells express keratins that are commonly 
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expressed in both basal and luminal mammary epithelial cell lines. Furthermore, we assessed 
three common markers for mammary stem cell plasticity and development (Lim et al., 2010). 
Both MEFS and M–EFPs were stained with CD24-PE, CD61-FITC, and CD29-APC antibodies. 
After performing fluorescent compensation, the samples were analyzed by flow cytometry as 
described earlier. MEFS have low CD24 positivity (35%) and high staining for CD29. As 
expected, MEFS were negative for CD61, a marker for the luminal progenitor population (Figure 
2.5D). The M–EFP cell line was largely CD24 positive (84%) and was also CD29 positive, 
although somewhat lower than the MEF cell line. Approximately 15% of M–EFP cells were 
positive for CD61, suggesting there is a subpopulation of cells with a luminal progenitor marker 
(Figure 2.5D).  
2.2.6 Genomic Analysis of M-EFP Suggests Shifts towards Mammary Development 
 GSA analysis comparing transcriptional factor networks (TFNs) demonstrated that the 
M–EFP cells were enriched in the transcription factors STAT5A and C/EBP. These are both 
involved in terminal mammary epithelial differentiation and development. The FREAC2 
(FOXF2) TFN, which has been shown to play an important role in tissue homeostasis through 
regulating epithelium-mesenchyme interaction to maintain epithelium polarity, was also elevated 
in M–EFPs (Aitola et al., 2000). SRF (serum response factor), which is involved in epithelial–
mesenchymal transition (EMT) and cellular proliferation, was significantly repressed in the M–
EFP cell line (Busche et al., 2008). To better illustrate the differences of these pathways between 
the MEFS and M–EFP cell lines, density plots demonstrate the significant pathway differences, 
seen in Figure 2.6B. We separated the MaSC  pL and pL  mL axis again in order to assess 
how transdifferentiation occurred along each axis, as we observed that the M–EFP cells 
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exhibited both basal (pL) and luminal (mL) characteristics, plotting each along the x and y axes, 
respectively.  
Our lab has previously demonstrated the utility of this algorithm across the human breast 
cancer subtypes. Comparisons in tumor types and mammary/breast development between human 
and mouse have been extensively studied (Visvader, 2009; Hollern and Andrechek, 2014) and 
the reported similarities provided the impetus to test this model with our mouse data. Initially, 
we examined mouse mammary tumor types to determine where they fall along the stem to 
luminal axes similar to their human counterparts. The C3(1)-Tag mouse model gives rise to 
basal-like tumor and falls in between the MaSC  pL axis in line with human basal tumors 
(Figures 2.1A and 2.6C) (Pfefferle et al., 2013). HC11, an immortalized mouse mammary 
epithelial cell line with basal-like features, exhibits a similar score along the axis. The mouse 
model MMTV-neu, a luminal tumor type, has the highest d-score among the mouse tumor/cell 
lines. However, due to the subtle differences in ESR1 and PGR regulation between human and 
mouse tumors, the d-score for human luminal tumors is higher relative to its mouse equivalent. 
MMTV-PyMT tumors are well characterized for their metastatic potential, which may explain 
why they are lower on the d-score than the MMTV-neu (Hollern and Andrechek, 2014). The 
PyMT cell line was derived from a C57BL/6 PyMT tumor and grown in vitro for several 
passages, which may also help explain why this derived cell line is slightly different from its 
FVB in vivo counterpart. 
 Our M–EFP cell line had a similar degree of movement along the MaSC  pL axis as 
the mammary norm tissue (p = .56) and significantly shifted from the parental MEFS (Figure 
2.6C-ii). Interestingly, when M–EFP cells are treated with 17β-estradiol and progesterone for 4 
days, the cells shift dramatically towards a pL phenotype relative to the cells without hormone 
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stimulation, while there is no significant movement along either axis when adding 17β-estradiol 
and progesterone to the parental MEFS (Figure 2.6C-ii). As a result, their score on the MaSC 
 pL axis is indistinguishable from the mammary lactating group (p = .44), suggesting that 
ligand-dependent activation of ESR1 and PGR are important for lactation (Brisken and 
O’Malley, 2010). The M–EFP cells were defined as being somewhat more differentiated on the 
pL mL axis, as compared the M–EFP cells treated with hormones. ESR1 and PGR are known 
to activate bipotent/progenitor cell division when undergoing branching morphogenesis and/or 
alveologenesis (Brisken and O’Malley, 2010). A hormonally induced increase in proliferation 
would explain the decrease in d-score along the pL  mL axis. Mature luminal cells are 
generally nonproliferative, and increased proliferative gene expression profiles result in a lower 
d-score.  
2.2.7 M–EFP Exhibit Estrogen-Dependent Growth 
In order to determine ESR1 responsiveness in the M–EFP cell line, cells were treated 
with various concentrations of 17β-estradiol, ranging from 10pM to 10uM for 4 days, and 
assessed for proliferation (Figure 2.7A). While the parental MEFS lacked a response to 17β-
estradiol after 4 days of treatment, the M–EFP cell line exhibits a concentration-dependent 
response with maximal effect at around 1 nM 17β-estradiol. The growth of M–EFP cells in 
standard culture medium containing phenol red was inhibited by the ESR1 antagonist tamoxifen 
with a calculated IC50 of 200 nM, whereas MEF cells were over 10-fold less sensitive to 
tamoxifen (Figure 2.7B). The growth responses to 17β-estradiol and tamoxifen were influenced 
by the presence of phenol red in the culture medium, which is well documented to have 
estrogenic activity (Welshons et al., 1988). Thus, the addition of 10 nM 17β-estradiol to phenol 
red–free media at 10 nM resulted in a loss of sensitivity in the M–EFP cells (Figure 2.8). Since 
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low proliferation rate as assessed by KI67 expression is a hallmark of the luminal A phenotype in 
human tumors (Inic et al., 2014), we examined KI67 expression by both qPCR and 
immunofluorescence (Figure 2.7C-D). M–EFP has significantly less KI67 expression than by 
MEFS (p = .0047, unpaired t test, 2-tailed), and less than HC11 and PyMT cell lines. This was 
confirmed by KI67 immunofluorescent staining; thus M–EFP cells cycle slower than their 
parental counterparts. 
2.2.8 M-EFP Cell Line Is Responsive to Milk Producing Stimulus In Vitro 
The primary specialized biological function of the normal breast or mammary gland is to 
produce milk when needed. Thus, the ability to synthesize milk components in response to 
prolactin is a key feature of differentiated breast luminal cells. After characterizing the 
morphological and genetic changes in the M–EFP cell line, we next sought to determine if these 
cells are responsive to prolactin. The MEFS and M–EFP cells were cultured either as monolayers 
in culture dishes or in Matrigel and stimulated with 100 ng/ml prolactin for 4 days. First, 
prolactin receptor (PRLR) protein levels were assessed since receptor activation is necessary for 
milk protein production. The 3 PRLR isoforms were expressed in M–EFP cells, whereas MEFS 
exhibited no expression of the long isoform and lower levels of the short isoforms than the M–
EFP cell line (Figure 2.9A). PRLR expression in the M–EFP cells was confirmed by 
immunofluorescence (Figure 2.9B). We then assessed the ability of the cells to respond to 
prolactin by producing the milk proteins β-casein (CSN2) and whey-associated protein (WAP) 
(Figure 2.9A). M–EFP cells expressed both CSN2 and WAP in the prolactin-stimulated cells, 
with a lower amount of CSN2 detected in the M–EFP cells not treated with prolactin.  
We further performed immunofluorescence for localization of PRLR and CSN2 in 
Matrigel cell cultures. Consistent with the Western blot results, the MEFS did not stain for PRLR 
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or CSN2 whereas M–EFP cells exhibited positive staining for both proteins. Not all PRLR-
positive cells stained positively for CSN2, and CSN2 appeared to be present in the matrix around 
the cells, as well as within the cells, suggesting that it is secreted or released from the cells 
(Figure 2.9B). Consistent with the GSA STAT5A pathway enrichment in the M–EFP cells, we 
confirmed STAT5A and phosphorylated STAT5A expression in M–EFP by Western blot in both 
prolactin stimulated and naïve cells by Western blot (Figure 2.10). These results suggest that the 
M–EFP cells expressed pregnancy/lactation-specific genes not otherwise activated in nonbreast 
cells as with the MEFS.  
2.3 Discussion 
Efforts to create a breast luminal cell line in vitro have been futile thus far. Studies have 
been largely focused on the reprogramming of differentiated breast cancer cell lines into breast 
cancer stem cells containing bipotent capacities. Our scientific approach here was two-fold: first, 
determining the appropriate combination of TFs necessary to create a cell line with luminal 
characteristics, and secondly, achieving this in the appropriate host cell line.  
We began with a simple hypothesis that the TFs required for luminal cell characterization 
and maintenance would be TFs enriched in luminal A tumors relative to all other tumor types 
(luminal B, HER2-enriched, basal, claudin-low). Our lab has shown significant overlaps of 
expression signatures between breast cancer subtypes and their corresponding normal 
counterparts (Prat et al., 2013); hence the TFs found in the tumor data set may be relevant for 
normal development. As mentioned earlier, several of these candidate TFs have been extensively 
studied in luminal breast cancers, and have roles in development (Kratochwil et al., 2003; Yeh, 
2003; Bernardo et al., 2010; Brisken and O’Malley, 2010), milk production (Neville et al., 2002; 
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Brisken and O’Malley, 2010; Rajaram and Brisken, 2012), or growth (Lange et al., 1999; Wu et 
al., 2006; Thorner et al., 2010; Hasegawa et al., 2015). 
We began transducing each of the 9 candidate TFs into BABE mammary epithelial cells 
to assess whether the TFs could induce luminal cell characteristics. Immediately, we noticed that 
the BABES transduced with either AR or ESR1 exhibited low proliferation rates, as determined 
by both the MTS proliferation assay, as well as EdU incorporation (Figure 2.1B-C).  Functional 
pathway analysis of gene expression profiles (Figure 2.1D) revealed activation of 
p53/Rb/p15/p21 pathways in the BABE–ESR1 cells relative to GFP control, which explains why 
BABE–ESR1 cells grow so slowly. While some previous studies have reported opposing effects 
of estrogen and progesterone on breast cell proliferation (Mauvais-Jarvis et al., 1986), 
coexpression of PGR together with ESR1 and FOXA1 in our BABE model did not reverse the 
growth suppression (data not shown). However, the combination resulted in a higher d-score 
than for either gene alone, indicating that the combination may interact to promote luminal 
differentiation in our system. Because BABES are hTERT immortalized, major cell cycle control 
pathways are still intact, so growth suppression and senescence likely would continue to be 
barriers to creating a continuous cell line model going forward.  
Several studies have suggested GATA3 is involved in luminal differentiation and 
hormone responsiveness (Koboldt et al., 2012; Cohen et al., 2014; Kong et al., 2011). 
Furthermore, GATA3 is part of the luminal A tumor signature and is significantly mutated in 
luminal A tumors relative to all other tumor types (Perou et al., 2000; Koboldt et al., 2012). In 
our BABE system, GATA3 produced the highest shift in d-score as a single transduced gene, as 
well as in combination with ESR1 (Figure 2.1A). Although for some TFs the MEF system 
proved to be more dynamic for revealing induced d-score shifts, in the mouse model, GATA3 
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failed to produce a meaningful increase in d-score or morphology change compared to our other 
candidate combo, M–EFP (Figure 2.3C). It is possible that no effect of GATA3 was observed in 
MEFS because in these cells it may induce genes that could obscure the d-score algorithm: for 
example,  immune-regulated genes, as GATA3 is a known regulator of Th1-Th2 development 
(Fang et al., 2007; Prat et al., 2010). It is also possible that GATA3 is involved in the expression 
of endogenous ESR1, as this was the case in our GATA3-induced BABE cell line (Figure 2.11). 
This may explain in part why the addition of both genes ectopically does not confer a more 
differentiated phenotype. Finally, it is likely that GATA3 functions differently in different cell 
lineages or in the mouse, so that GATA3 may have more pronounced effects in a lineage-
committed basal-like breast epithelial cell line than in a dedifferentiated embryonic cell line, as it 
is thought that GATA3 exerts its influence later in development, particularly during pregnancy 
(Asselin-Labat et al., 2007). Interestingly, although ESR1 and GATA3 are known to induce 
expression of each other in mammary epithelial cells, there was very little GATA3 expression in 
the M–EFP cell line, which may reflect the predominantly progenitor phenotype of these cells.  
The creation of our MEF cell model that exhibited maximal transdifferentiation toward a 
breast luminal epithelial phenotype depended on two main conditions: first, using a combination 
of genes, with EFP acting together to yield the best d-score (Figure 2.3C), and second, the 
absence of serum during the transdifferentiation process. We serum-starved parental MEFS for 
72 hours, ran them on microarrays and tested their d-score as well (data not shown). While the 
MEFS without serum displayed an increase in d-score relative to parental MEFS and M–GFP 
grown in serum, the genes involved in that increase were proliferation related and not breast-
specific genes. Moreover, the MEFS in serum-free media did not exhibit a cobblestone 
morphology similar to the M–EFP, again showing serum starvation by itself does not promote 
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epithelial transformation and that the ectopic expression of EFP was required for that 
transformation to occur (Figure 2.3E).  
The M–EFP cell line gained expression of key epithelial markers such as KRT14 and 
CDH1 and lost expression of one key mesenchymal marker, COL1A2. While M–EFP cells still 
maintained some level of Vimentin protein expression by immunofluorescence, CDH1 
expression significantly increased relative to the parental MEFS, suggesting that epithelial 
transformation was occurring (Figure 2.4A-B). Increased cell–cell adhesion was evinced by the 
change in cell growth pattern from single discohesive cells to epithelioid colonies. To further 
confirm mesenchymal-to-epithelial transformation in these cells, phalloidin was used to 
demonstrate that the organization of F-actin stress fibers found in mesenchymal fibroblasts had 
changed to a cortical localization adjacent to the plasma membrane (Figure 2.4C). 
Our M–EFP cell line furthermore expressed markers considered to be specific to both 
basal and luminal subclasses, including the positive expression of KRT 5 and 18, and breast 
lineage markers CD24 and CD29. KRT5 expression is associated with the basal-like subtype of 
breast cancer, MaSC, and progenitor normal cell types, while KRT18 expression is associated 
with luminal subtype of breast cancer and luminal normal cell types (Graham et al., 2011). By 
FACS analysis, M–EFP are CD24high/CD29high, which could be considered a progenitor cell 
(Figure 2.5B-C) (Sleeman et al., 2006). CD61 is normally expressed in the luminal progenitor 
population and lost in the MaSC and mature luminal fractions of normal mouse breast epithelial 
cells. We confirmed that a subpopulation of the M–EFP cells are CD61 positive (15%), which 
may be explained by one of several hypotheses (Lim et al., 2010). These cells may be more on 
the MaSC side of the MaSC pL axis with movement towards the pL phenotype, or they may be 
more on the mL side of the pL  mL axis. It is difficult to know for sure since they have high 
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CD29 but also express KRT18. Interestingly, we did not see any significant shift in EpCAM by 
FACS in either the single transduced BABES (data not shown) nor in M–EFP (Figure 2.12). This 
might be interpreted as showing a largely basal-like phenotype, despite their CD24 positivity, as 
EpCAM has been shown previously to better separate the luminal and basal populations more 
effectively than CD24 alone (Visvader and Stingl, 2014).   
GSA afforded a glimpse into the regulatory networks that may be influencing the M–EFP 
phenotype. While future studies utilizing ChIP-seq would be more informative, the results from 
GSA suggested that transcriptional factor networks enriched in the M–EFP cell line relative to 
MEFS were involved with lumen formation in breast development (C/EBP β) and alveolar 
formation in pregnancy (STAT5A, FREAC2). Notably, both C/EBP β and FREAC2 (FOXF2) 
have been shown in previous studies to preferentially bind at PR promoter sites in breast and 
uterine cell lines (Yin et al., 2012), and C/EBP β is a known downstream target of PGR (Lange 
et al., 1999). In addition, several of the TF networks down in the M–EFP cells relative to MEFS 
are involved in EMT, which explains the change in morphology as seen in Figures 3E, 5C. Based 
on our data demonstrating that the M–EFP cells comprise a mixture of breast lineage and cancer 
subtype characteristics, we decided to examine the d-score as a two-dimensional spectrum rather 
than define it as a score determined by the addition of the two developmental axes.  
It is worthwhile to note that there is not a mouse mammary cancer cell line that embodies 
the mature luminal characteristics of human luminal tumors. This is in large part due to the fact 
that mouse mammary tumors have lower ESR1 and PGR relative to human breast tumors, 
demonstrating why luminal-like mouse mammary tumors have more a progenitor luminal than a 
mature luminal phenotype. Treating M–EFP cells with 17β-estradiol and progesterone 
significantly increased their movement towards a progenitor phenotype, suggesting that ectopic 
 
 
66 
expression of the receptors may need ligand-dependent signaling to further differentiate. Further 
studies will need to demonstrate this is indeed the case. 
While we have shown the activities of an agonist and an antagonist of ESR1 in the M–
EFP cell line, curiously, MEFS have some endogenous ESR1 expression and yet do not respond 
to 17β-estradiol nor tamoxifen (Figure 2.7A), indicating their lack of estrogen-dependent growth. 
The IC50 of tamoxifen for M–EFP was roughly 10-fold less than the MEF cell line (Figure 2.7B); 
however, the sensitivity of M–EFP to tamoxifen is still less than that of the human luminal B 
breast cell line MCF-7, as reported by other labs (Lippman et al., 1976; Masamura et al., 1995; 
Hoffmann et al., 2004). However, M-EFP cells do respond to estradiol at similar concentrations 
to MCF-7 cells that have been grown in “normal” conditions (i.e., in phenol-red media) 
(Masamura et al., 1995). One explanation for these differences in sensitivity to tamoxifen and 
estradiol could be cell type, as MCF-7 cells are a cancer cell line, and the M–EFP cell line is 
immortalized but not transformed. While M–EFP cells exhibit responses to estrogen receptor 
signaling, they do not appear to be dependent on it for growth. In addition, they are not rapidly 
proliferating cells and thus may be less affected by down-regulation of the receptor. Finally, our 
M–EFP cell line is not grown in serum-containing media, and unlike the 17β-estradiol 
stimulation assay, the tamoxifen assay was performed in phenol-red media. After several 
attempts with phenol-red free media, with and without added 17β-estradiol, the cells were not 
only much more resistant to tamoxifen, they did not grow as well (data not shown). It is plausible 
that there are clear media differences beyond the dye component that affect their response to 
estrogen signaling, or more simply, phenol red may sensitize the cells to tamoxifen (Berthois et 
al., 1986). By contrast, the presence or absence of phenol red did not affect growth of the 
parental MEFS.   
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Studies have shown that PGR is necessary for alveologenesis and further side branching 
during pregnancy. Downstream signaling pathways are induced including PRLR and STAT5A, 
and upon stimulation by prolactin, milk proteins are ultimately produced. In mouse models 
lacking PRLR, STAT5A phosphorylation and production of the milk proteins WAP and β-casein 
is lost (Brisken et al., 1998). In this study, we demonstrated that M–EFP cells not only have 
STAT5A protein expression (Figure 2.10) but also enriched expression of STAT5A downstream 
targets as determined by GSA (Figure 2.6A-B). Along with STAT5A, there is PRLR co-
expression (Figure 2.9A-B), which is required for milk production. While murine PRLR receptor 
isoforms are seen in a variety of cell types, the short and long isoforms (4 total, including 2 short 
isoforms) are responsible for reproductive development and lactogenic responses (Binart et al., 
2003, 2010). We detected these 4 isoforms in our MEF model cell lines, and importantly, we 
found that that the long form is uniquely expressed in the M–EFP cell line (Figure 2.9A). We 
also considered whether PR/PRLR/STAT5A signaling alone is sufficient to induce milk 
production in any cellular context, or if the ability to produce milk depends on other “classical” 
mammary epithelial characteristics. Some of the established characteristics of mammary 
epithelial cells in culture include, but are not limited to, the formation of acini-like spheroids, 
polarization of the epithelial cell layers, and basal deposition of basement membranes (Debnath 
et al., 2003b; Tallkvist et al., 2015). Are external cell environmental cues leading to the 
establishment of cell polarity and acinic structures necessary for successful milk production? A 
mouse mammary epithelial cell line, HC11, is less differentiated than our M–EFP cells by d-
score but when cultured in Matrigel produces acini-like spheroids and milk-producing features 
(Marte et al., 1995; Helguero et al., 2005). In our M–EFP model, the milk proteins WAP and β-
casein were produced by prolactin stimulation; even the cells were grown as monolayers in 
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plastic culture dishes, as well as in Matrigel. Thus, expressing the EFP TF combination allowed 
MEFs to acquire the intracellular machinery to produce milk components without requiring a 
specific matrix interaction. However, the normal 3-D architecture may require the extracellular 
matrix environment to shape the ability of the cells to form polarized functional glands that 
ultimately deliver the milk product to the offspring.   
To conclude, we demonstrated that transdifferentiation from one lineage to another via 
defined transcription factors could occur in a well-defined growth environment without a need 
for serum to provide additional factors. We also found that the selection of the starting cell line 
for transdifferentiation is paramount. Although the BABE cells are part of the same breast 
epithelial lineage as luminal-like cells, expressing the same set of 3 transcription factors in a 
mesenchymal cell line yields a much larger shift in d-score, morphology, and most importantly, 
function. We created a directly transdifferentiated cell line with epithelial and breast-specific 
characteristics, including proliferation dependence on estrogen receptor signaling and prolactin-
stimulated milk production.   
This initial work to create and characterize our luminal cell model opens the door to a 
variety of future directions to further characterize the model and to employ it to answer questions 
about luminal cell biology. The effects of various hormones on the breast are known to be quite 
complex. We have already found that the addition of such hormones to our M–EFP cells moves 
them significantly in d-score toward a more differentiated state, so more involved studies 
addressing hormone responses in our model would be enlightening. Secondly, can these cells be 
employed to create a model of mammary development and function in mice? Can they 
repopulate a mammary fat pad and create mammary gland architecture? Most importantly, are 
these cells truly reprogrammed? This question might be addressed by knocking out the 
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transduced genes to determine if the cells lose differentiation or function in the absence of one or 
more of the transcription factors? This work has produced a useful tool for understanding breast 
development, and the process can be used to offer greater insight toward the development of a 
mammary differentiated luminal A line, one whose growth in vitro has eluded scientists to date.  
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Table 2.1. Transcription Factor Candidate List 
GENE ACCESSION No. 
AR NM_000044 
DACH1 NM_080759 
ESR1 NM_000125.3 
FOXA1 NM_004496.3 
GATA3 NM_001002295.1 
LEF1 NM_016269.4 
MYB NM_001130173.1 
PGR NM_000926.4 
XBP1 NM_005080.3 
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Figure 2.1. TF Characterization in the BABE Cell Line 
 
 
(A) D-score analysis and comparison across transduced BABEs, breast cancer cell lines, and 
tumors. (B) 4-day MTS assay comparing proliferation across the 9 different TF-induced BABE 
cell lines as compared to BABE–GFP control. *** p = .0001 for ESR1, error bars = SD. (C) 
FACS analysis of BABES with empty vector and BABES–ESR1 stained for EdU–FITC. 
Population of cells with EdU positivity are labeled by percentage. (D) Cytoscape illustration of 
cell cycle pathway. SAM analysis of cell cycle genes enriched in BABES–ESR1 relative to 
BABES–GFP control. Fold change is indicated by color, with red for higher expression in –
ESR1 cells and green for higher expression in –GFP cells.  
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Figure 2.2. Cell Cycle Gene Expression Analysis of Single Transductants in the BABE Cell Line 
 
(A) TF combination screen setup in the MEF cell line. (B) Table of all the single and multiple TF 
combinations screened. (C) D-score analysis of the TF combinations screened in the MEF cell 
line, which include biological replicates of M–EFP. Cell lines HC11 and PyMT included as 
reference for basal and luminal-like, respectively. (D) Western analysis of proteins ESR1, 
FOXA1, PGR, and β-actin as a loading control in MEFS and M–EFP. As a reference, HC11 and 
PyMT cell lines are included. (E) Brightfield microscope image of MEFS and M–EFP at a 
magnification of 10X. 
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Figure 2.3. Initial Transduction Experiments in the MEFS 
 
(A) TF combination screen setup in the MEF cell line. (B) Table of all of the single and multiple 
TF combinations screened. (C) D-score analysis of the TF combinations screened in the MEF 
cell line, which include biological replicates of M–EFP. Cell lines HC11 and PyMT included as 
reference for basal and luminal-like, respectively. (D) Western analysis of proteins’ ESR1, 
FOXA1, PGR, and β-actin as a loading control in MEFS and M–EFP. As a reference included 
are HC11 and PyMT cell lines. (E) Brightfield microscope image of MEFS and M–EFP at a 
magnification of 10X.  
  
 
 
74 
Figure 2.4. Epithelial Characterization of M–EFP Cell Line 
 
(A) Real-time PCR analysis of mesenchymal/epithelial gene expression in the parental MEF and 
M–EFP cell lines. (i) Data were normalized to housekeeping gene TBP; ∆∆𝐶𝑡 values of M–EFP 
are relative to MEFS. Error bars are SD. (ii) Table of relative fold-change values for genes 
KRT14, E-Cadherin, Vimentin, and Col1A2 from graph in (i). (B) Immunofluorescence of the 
following, from left to right: DAPI, Vimentin, Pan-Cytokeratin, merged, in parental MEFS and 
M–EFP. Magnification at 20X. (C) Immunofluorescence of the following, from left to right: 
DAPI, E-Cadherin, ERBB3, merged, in parental MEFS and M–EFP. Magnification is 20X. (D) 
Immunofluorescence of phalloidin-red and DAPI staining in both the parental MEFS and M–
EFP. (i) Magnification at 40X with oil. (ii) Zoomed-in view of F-actin staining.   
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Figure 2.5. Interrogation of Breast-Specific Phenotypic Markers in the M–EFP Cell Line 
 
(A) Brightfield microscope image of MEFS and M–EFP grown in 3-D Matrigel. Magnification 
at 20X. (B) Western analysis of breast markers KRT5, KRT18, E-Cadherin, and α-Tubulin as a 
loading control in both MEFS and M–EFP cells. (C) Immunofluorescence of the following, from 
left to right: DAPI, KRT18, KRT5, merged, in parental MEFS and M–EFP grown in matrigel. 
Magnification at 20X. (D) FACS analysis of breast lineage markers in MEFS and M–EFP. (i) 
CD24 and CD29, and (ii) CD24 and CD61. A total of 15,000 events were collected for each 
sample.  
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Figure 2.6. Breast-Specific TFT Enrichment and Differentiation Analysis  
(A) Table of TF networks significantly up/down regulated in M–EFP relative to parental MEFS. 
GSA FDR < .5 for all listed TFT. (B) Hierarchical cluster of TF networks involved in breast 
development. TFT clusters’ (i-iv) are comprised of transcription factors and their downstream 
targets, as described previously (Xie et al., 2005). (i) Cluster of CEBPB_02 (C/EBPβ) 
downstream target genes. (ii) Cluster of FREAC2_01 (FOXF2) downstream target genes. (iii) 
Cluster of STAT5A_02 (STAT5A) downstream target genes. (iv) Cluster of SRF_Q6 (SRF) 
downstream target genes. (C) D-score assessment via each of the two lineage vectors  MaSC 
pL, and pL mL. (i) Scatterplot of d-score, by axis. The X-axis is the MaSC  pL vector, 
while the Y-axis is the pL  mL vector of the d-score. All mouse groups are labeled and 
individual samples are represented by a +. (ii) Bar graph depicting individual vector data across 
MEF, cell line and tumor/tissue groups. M–EFP treated with hormones’ EP and mammary 
lactating groups not significantly different in either lineage vector, p =.44, p = .51. M–EFP and 
mammary normal group significantly different along pL  mL vector, p = .042, and similar 
along the MaSC pL vector, p =  0.56.  
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Figure 2.7. ESR1 Responsiveness and KI67 Expression 
 
(A) MEFS and M–EFP cells were treated with varying concentrations of 17β-estradiol in phenol 
red-free media for 4 days then assessed for proliferation. (B) MEFS and M–EFP cells were 
treated with varying concentrations of tamoxifen in phenol red media for 4 days then assessed 
for proliferation. IC50 value for M–EFP is 200 nM. (C) KI67 expression in MEFS, M–EFP, 
HC11, and PyMT cells by real-time PCR. Samples were normalized with housekeeping gene 
TBP. *p = .0047, error bars = SD. (D) Immunofluorescence staining from left to right: DAPI, 
KI67, merged. Magnification is 20X.  
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Figure 2.8. 96 hr Treatment with Tamoxifen in Phenol-Red Free Media 
 
 
IC50 of M–EFP is 1.82 uM, while MEF IC50 is 23.92 uM. 
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Figure 2.9. M–EFP Exhibit Breast Functional Characteristics 
 
  
(A) Cells were treated with +/- prolactin for 4 days. Then protein expression of PRLR, CSN2, 
WAP, and α-Tubulin (loading control) was determined via Western blot. (B) 
Immunofluorescence of MEFS and M–EFP in Matrigel, from left to right: DAPI, PRLR, CSN2, 
merged. Magnification is 20X.  
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Figure 2.10. STAT5A Activation in Prolactin Treated M–EFP Cells 
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Figure 2.11. TF Regulation in the BABE Cell Line 
  
BABES 
transduced  
with each of the 
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Figure 2.12. EpCAM/CD49f FACS Analysis in the Mouse Model 
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CHAPTER 3: ROLE OF GATA3 IN BREAST DEVELOPMENT  
AND LUMINAL TUMORS 
Introduction 
GATA binding protein 3 (GATA3) is a member of the GATA family of transcription 
factors. There are 6 members of the GATA family that are tissue specific. GATA3 has critical 
roles in the development of T cells and the kidney, mammary, and neural tissues (Grote et al., 
2008; Hendriks et al., 1999; Kouros-Mehr et al., 2006; van Doorninck et al., 1999). In addition to 
its role in tissue differentiation, GATA3 is essential for proper embryonic development, as 
GATA3-mutant mice die at embryonic day 11 or 12 post coitum due to severe CNS 
abnormalities and deficiencies in liver hematopoiesis (Pandolfi et al., 1995), while in humans, 
GATA3 mutations result in hypoparathyroidism, renal dysplasia syndrome, and deafness (Nesbit 
et al., 2004; Van Esch et al., 2000). 
GATA3 is a transcription factor that binds to either a consensus (A/T)GATA(A/G) 
sequence or palindromic site (ATCWGATA, W = A/T). GATA3 regulates target genes by 
directly binding to target promoter sequences or through long-range chromatin remodeling and 
DNA looping (Chen et al., 2012; Theodorou et al., 2012). Studies with X-ray crystallography 
were determined how GATA3 binds to DNA. The DNA binding domain (DBD) of the human 
GATA3 protein (amino acids 260-370) contains two zinc fingers, which are also known 
collectively as the N and C finger, for zinc finger 1 and zinc finger 2, respectively (Figure 3.1). 
Adjacent to the N and C fingers are critical basic regions that help facilitate the binding to 
GATA consensus sequences. The N and C fingers can bind to DNA independently of each other 
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and also have slight differences in sequence preference (Pedone et al., 1997; Visvader et al., 
1995). Recently it has been discovered that GATA zinc fingers can bind to DNA via two 
different mechanisms: (a) both zinc fingers wrapping around a single palindromic GATA site 
and (b) a bridging method, where each N or C finger binds to two separate DNA molecules 
(Chen et al., 2012). Two more regions of the GATA3 protein important for DNA binding 
stability and regulation are the linker region and the C-terminus tail (C-tail). The linker region, 
located between the N and C fingers, is a highly basic region that allows for significant 
conformational flexibility, particularly when the N and C fingers are bound to different DNA 
strands. This allows for the simultaneous long-range regulation of multiple genes. While the 
amino acid sequence of the linker is similar to the C-tail, their functions are different. The C-tail, 
like the linker, contains a series of basic residues; however, the C-tail acts as a stabilizer, binding 
to the minor groove of DNA, wrapping itself around the DNA, to reach the N-finger (Chen et al., 
2012). The dual role of the zinc finger domains combined with the flexibility of the linker region 
may result in effective lineage control during development. 
GATA3 increases enhancer accessibility for ESR1-mediated transcription, in part 
explaining the significant correlation in expression to the luminal subtype of breast cancers 
(Theodorou et al., 2012). Evidence has suggested that GATA3 may act as a tumor suppressor, as 
ectopic expression of GATA3 results in reversal metastasis, induction of mesenchymal-epithelial 
transition, and loss of tumor dissemination (Dydensborg et al., 2009; Kouros-Mehr et al., 2008; 
Yan et al., 2010). However, in addition to directly regulating ESR1 expression, GATA3 
upregulates genes involved in oncogenesis (Eeckhoute et al., 2006; Jiang et al., 2010). Promoter 
analysis of GATA3 target sites has demonstrated differential binding patterns between normal 
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and cancer cell lines, implying that the function of GATA3 is mediated in part by the oncogenic 
activity of the cell line (Cohen et al., 2014).  
Recently, efforts have focused on genomic sequencing of tumors to better understand 
mutational drivers of disease. Several groups have published reports on GATA3 mutations in 
breast cancer patient samples following an initial report from our lab in 2012 (Arnold et al., 
2010; Koboldt et al., 2012; Usary et al., 2004). Interestingly, the vast majority of GATA3 
somatic mutations are found within luminal A tumors, further suggesting the existence of a 
relationship between GATA3 and ESR1 signaling in these tumors. Somatic mutations of GATA3 
have been found enriched in a few key domains of the protein: Exons 4-6, which comprise the N 
and C fingers (DBD), as well as a portion of the C-tail, and the C-terminus (largely at the end of 
the protein, which does not have known motifs). DBD mutations would be expected to affect 
DNA binding, as the N and C fingers are responsible for the recognition of GATA-specific and 
palindromic motifs. To characterize the functional consequence of DBD mutations, the luminal 
B cell line, MCF-7, contains a GATA3 mutation, a nucleotide (G) insertion at position 1566, 
which is located in the DBD. Comparing the mutant MCF-7 with MCF-7 overexpressing wild-
type GATA3 resulted in a differential loss of key GATA3 downstream target genes in the mutant 
cells (Cohen et al., 2014). This mutation confers a truncated GATA3 protein, which, in addition 
to DBD malfunction, may also affect the stability properties of the C-tail. Mutations in the C-tail 
may influence GATA3 stability on the DNA molecule, as binding the minor groove provides 
this. Strikingly, the TCGA breast cancer data set published in 2012 not only confirmed that 
GATA3 mutations were present significantly in luminal A tumors compared to all other intrinsic 
subtypes, but there were a significant number of mutations at the C-terminus between amino 
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acids 400–440 (Koboldt et al., 2012). The significance of this is yet to be understood due to the 
lack of known motifs or function within the last 40 amino acids of the protein.   
Based on the locations of the GATA3 mutations found in our lab and others, I want to 
further understand the functional consequences of these mutations, particularly at the C-
terminus, and how this region impacts the binding and regulation of ESR1-responsive genes. In 
the larger context, discerning the function of these mutations may help define the role of GATA3 
in these cells. Does it act as a tumor promoter, or accentuate the ESR1 phenotype, giving these 
luminal A tumors a good prognosis relative to the other tumor types? I began by developing a 
transfection system and followed with structured bioinformatics analysis. Continuing 
experiments include the creation of the mutant GATA3 constructs from the distinctive regions of 
high mutational activity in the C-terminal tail as reported in the TCGA data (Koboldt et al., 
2012). The work performed in this chapter describes that analysis, which sets the stage for others 
to pursue experimental validation of several hypotheses. 
3.1 Methods 
3.1.1 GATA3 Expression and Reporter Plasmid Construction 
The GATA3 wild-type sequence was obtained from the Harvard Human ORFeome, 
Version 5.1 (http://horfdb.dfci.harvard.edu/hv5/). The open reading frame (ORF) sequence 
corresponded to NCBI accession # BC006793. The GATA3 ORF was in a pDONR223 plasmid, 
making it compatible with GATEWAY technology (LifeTechnologies, Inc). A lentiviral 
mammalian expression plasmid that was GATEWAY compatible was chosen as the destination 
vector for wild-type GATA3 and had the following features: PGK promoter with Neo resistance 
(pLENTI-PGK-DEST vector, Addgene.org). Recombination of GATA3 ORF into the pLENTI-
PGK-DEST vector was performed as recommended by Invitrogen’s GATEWAY protocol. In 
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addition, GATA3 cDNA inserted into a pBABE-puro retroviral vector (http://www.addgene.org) 
was also tested. Two forms of DNA were used to amplify the FOXA1 region of interest. 
Genomic DNA from normal human females (a kind gift from the D. Eberhard lab, UNC) and a 
BAC clone that spans 2.4kb of FOXA1 promoter–5’ RNA sequence were both tested as 
templates to create a GATA3 binding sequence for the reporter construct (BAC clone RP11-
356O9, Empire Genomics). A 1.5kb sequence flanking FOXA1 promoter and 5’ RNA sequence 
were generated with the following primers: FOXA1-F : CCGCAGTGCAGATGCGTTCCC and 
FOXA1-R: TCACCTCCTGCGTGTCTGCGTAGT. Subsequently, the amplified FOXA1 
sequence was cloned into a pGL4.17-luc reporter construct (Promega) after adding restriction 
sites Sac1 and HindIII to the FOXA1 F and R primers. The FOXA1 insert was validated by 
restriction digest and sequencing. 
3.1.2 Cell Culture and Transfection  
The 293T cells used for the luciferase assay were grown in DMEM-high glucose (Gibco, 
Life Technologies) with 10% FBS with 100X pen–strep when expanding for experiments. 
During the selection process, 293T cells were placed in expansion media with the addition of 
either 200 ug/ml G418 (Gibco, Life Technologies), 1 ug/ml puromycin (Invitrogen, Life 
Technologies), or both. Prior to the transfections, 293T cells were plated at a density of 4 x 104 
in 24-well plates. Next, 1 ug of pGL4.17-FOXA1-luc, pGL4.17-luc, and pBABE-GATA3-puro 
each was added with 3 ul Fugene transfection reagent (Roche) in 200 ul of media without 
antibiotics. This sat at room temperature for 20 min. For the plasmid combinations, 1ug each 
plasmid was used. There were 3 conditions total and each was run in triplicate: pGL4.17-luc only 
(neg ctrl), pGL4.17-FOXA1-luc, and pGL4.17-FOXA1-luc + pBABE-GATA3-puro.  
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3.1.3 Luciferase Assay 
After 10 days, cells were washed in 1X PBS. 100 ul of reporter lysis buffer from the 
Luciferase Assay System (Promega), which was added to each well. Then they were 
immediately placed on dry ice. Once frozen, the cells were placed in 37 °C until warmed. Next, 5 
or 20 ul of each replicate was added to white luminometer plate, and 100 ul of luciferase assay 
reagent was added by injector to each well using a luminometer (Molecular Devices) with a time 
delay of 2 s and read time of 10 s. Both 5 and 20 ul of cell lysate was quantitated for protein. The 
luciferase signal was normalized to protein levels for each group.  
3.1.4 Structural Analysis 
The ExPASy (http://www.ExPASy.org) online tool was used to align multiple GATA 
family protein sequences within metazoans. There was a total of 1,000 sequences with 250 
alignments. Looking only at vertebrates, we accepted all sequences with an e-value of 10-6 or 
lower. In all, 250 sequences within vertebrates were used in the analysis. ClustalX 2.1 
(http://www.clustal.org) was used to visualize sequence similarities and conserved regions across 
the six GATA genes (1–6) aligned in ExPASy. In predicting protein-folding patterns and regions 
of disorder in mutated GATA3 sequences, the Regional Oral Neural Network (RONN) was used 
(https://www.strubi.ox.ac.uk/RONN). 
3.2 Results and Discussion  
Based on recent data, GATA3 mutations tend to occur in luminal A and B tumors, 
consistent with the expression patterns of GATA3 in both normal and cancerous luminal cells 
(Chou et al., 2010; Koboldt et al., 2012; Yoon et al., 2010). In this study we set out to determine 
the functional role of GATA3 mutations, focusing on the C-terminus, where mutations are 
common but the function is currently unknown. 
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Initially, we created a both a lentiviral and retroviral expression plasmid containing the 
wild-type GATA3 sequence (Figure 3.2). Due to the size of the vector and sequence, we went 
forward with the retroviral plasmid (pBABE-GATA3-puro). Others in our lab had success 
transfecting pBABE-GATA3-puro, so there was no immediate need for packaging the virus for 
infection. Previous microarray experiments using overexpressed pBABE-GATA3-puro in breast 
cancer cell lines SUM149 and SUM159 confirmed the expression of GATA3 and its downstream 
effector genes (data not shown). The pBABE-puro backbone was also used for expressing the 
GATA3 mutants. 
Since GATA3 is a transcription factor that recognizes specific GATA and palindromic 
motifs, we interrogated the promoter regions of genes known to be regulated by GATA3 in 
mammary development. Interestingly, we found several GATA3 binding sites in the FOXA1 
promoter region with the online tool, rVista 2.0 (http://rvista.decode.org). Other studies have also 
reported GATA3 acting upstream of FOXA1 signaling (Kouros-Mehr et al., 2006; Theodorou et 
al., 2012).  
The FOXA1 sequence encompasses some of 5’ RNA coding region, but the site lies 
predominantly upstream within the CpG island-heavy promoter regions (Figure 3.3). This 1.5kb 
region contains numerous CpG islands and has at least one published GATA3 binding site 
(Kouros-Mehr et al., 2006). We attempted to amplify this region with various primer pairs; 
however the CG-rich sequence made it difficult to amplify. Hence we shortened the sequence 
from 2 to 1.5 kb upstream from the ATG start site. A recently published paper had success 
amplifying this region, so we modified our primers using published primer sequences (Naderi et 
al., 2012). Initially, our DNA template came from a human female DNA sample used as a 
normal control for DNA sequencing. After several attempts to reduce nonspecific amplified 
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products, we ordered a BAC clone that contained the FOXA1 gene and its upstream sequence 
(Chr14 : 37,940,666-38,144,263, based on alignment from Feb. 2009-GRC37/hg19). Subsequent 
PCR amplifications suggested that the addition of DMSO helped resolve the sticking of DNA 
strands, allowing for more efficient amplification using both the genomic DNA and the BAC 
clone (Figure 3.4A). Finally, we cloned this fragment into the pGL4.17-luc reporter construct 
(Figure 3.4B), which was ready to be tested along with the ectopic expression of wild-type 
GATA3. 
There was a significant luciferase signal with the transfection of the pGL41.7-GATA3-
luc as compared to the pGL41.7-luc empty vector control; however, when we transfected both 
reporter and pBABE-GATA3 vector together, the luciferase signal decreased (Figure 3.5). The 
loss of the luciferase signal occurred in both cell quantities and was consistent regardless of 
whether normalization with protein concentration was performed. This was not the result we 
were expecting, though there are several possibilities as to why this may have occurred. First, the 
loss in signal with the pBABE-GATA3 may be due to less promoter construct entering the cell. 
Further experiments examining transfection times and sequences will need to be carried out. 
Because lipophilic-based transfections are much more inefficient in cellular incorporation than 
viral methods, one thought is to create virus for the wild-type GATA3 construct, create a stable 
cell line, and then transfect those GATA3-expressing 293T cells with the reporter plasmid. 
Another explanation lies within the biology of the FOXA1 promoter sequence. Our motif 
analysis showed that in addition to GATA3, several genes bind to the FOXA1 promoter region 
(data not shown). Therefore, it is possible that the addition of ectopically expressed GATA3 may 
indirectly affect the binding of TFs that bind to FOXA1, causing a decrease in signal compared 
to the reporter-only cells. This was hard to resolve as we did not determine which TFs (including 
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GATA3) were binding the reporter. Alternatively, repeating this experiment with a GATA3-
positive cell line such as MCF-7s can help objectively measure GATA3 activity without the 
technical obscurity of multiple transfection efficiencies. Likewise, with a positive control cell 
line, a luciferase reporter for a housekeeping gene would also be an effective indicator for 
transfection efficiency of both constructs. With the housekeeping gene reporter, luciferase signal 
is expected to be robust; however, transfection with an additional plasmid may affect its 
transfection and, thus, the signal. As illustrated, there is a high likelihood luciferase signal losses 
with dual transfections are due to technical reasons. Future experiments in addition to those 
mentioned will include the testing of sequential transfection and transduction methods with both 
reporter and expression plasmids.  
Recent studies in breast cancer have explored the frequency of mutations enriched within 
the intrinsic subtypes. GATA3 was shown to be mutated at a significantly higher rate within the 
luminal tumors (Koboldt et al., 2012). Further analysis determined an enrichment of mutations in 
the C-terminus of the GATA3 protein (Figure 3.6). In order to elucidate the role and 
consequences of GATA3 mutations, we set out to determine which protein domains within 
GATA3 are conserved across both the family of GATA proteins and across vertebrates. Two key 
observations were seen after the analysis. First, across all vertebrates, GATA3 was closest in 
sequence to GATA2, with a homology of 55% (Figure 3.7) (Chou et al., 2010). Likewise 
GATA3 is extremely homologous across mammals, with a 97% homology between human and 
mouse. Interestingly, GATA2 has been shown to facilitate androgen receptor (AR) signaling in 
prostate cells, suggesting a role for GATA2 in hormonal signaling (Wu et al., 2014). Finally, it is 
worth noting that the last several residues in GATA3 are not only conserved across mammals but 
also well conserved across some avian species (Figure 3.7).  
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Given the frequency of mutations in that region, coupled with the degree of conservation 
across avian and mammalian species, this region has an extremely important function in ESR1-
positive luminal breast tumors. The C-tail is a region rich with basic residues and is instrumental 
in establishing stability with DNA (Chen et al., 2012). Our lab sought out to determine the 
functional consequence of disrupting the C-tail region by site-directed mutagenesis at residue 
367, from a charged, basic Arginine to a hydrophobic Leucine (Usary et al., 2004). The ectopic 
expression of GATA3-R367L mutant resulted in RNA expression levels similar to the GATA3 
wild type in 293T cells. However, in contrast to the GATA3 wild type–expressing 293T cells, 
there was no nuclear GATA3 protein detected in the GATA3-R367L (Usary et al., 2004). It is 
possible that the Arginine to Leucine change in the C-tail rendered the protein unstable and 
unable to effectively bind to DNA within the nucleus.  
Armed with this information, we focused our current effort in three keys areas (Figure 
3.6). Due to the consistent reporting of the importance of the zinc finger domains, we planned to 
create a GATA3 mutant construct with the addition of an A at the Arginine residue 330. This 
would shift the amino acid sequence, resulting in an early stop codon, thus truncating the protein 
to 351 total amino acids. A previous study had similarly knocked out the C-finger function, 
which resulted in abrogated IL-4 and IFN-γ expression, demonstrating that loss of the C finger 
negatively affected binding to DNA (Ranganath and Murphy, 2001).  
The second region of interest is a highly mutated area in the more distal C-terminus 
beyond the basic C-tail (amino acids 385–440). In the TCGA breast cancer mutational analysis, 
there were 6 confirmed mutations in the luminal B cohort and 5 in the luminal A cohort at 
residue 409 (Koboldt et al., 2012) (Figure 3.7). Upon further inspection, sequencing results 
showed an insertion of a G at this location, resulting in an in-frame shift with a larger than 
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normal protein product of 509 amino acids (Figure 3.8). Likewise, our third proposed mutagen 
site is found at the extreme C-terminus at residue 431. Mutations were confirmed at residue 431 
in both luminal A and B patients and were either a TT insertion or a T deletion. Regardless of the 
type of mutation, the protein result was unchanged. As with the mutations seen at residue 409, 
the protein size was predicted to be 509 amino acids, significantly larger than its wild-type form 
(Figure 3.8).  
Recently, a published study examined the functional consequence of an elongated 
GATA3 protein based on the frequency of this mutation in the familiar disorder 
hypoparathyroid-deafness-renal (HDR) syndrome (Ali et al., 2007). Demonstrating that the 
elongation of the protein resulted in loss of DNA binding, Ali et al. also predicted that the excess 
amino acids interrupted the binding stability due to steric hindrance. It is not known, however, 
how these structural and functional defects contribute/correlate with the luminal phenotype as 
seen in breast cancer.  
Due to the growing evidence that C-terminus mutations in GATA3 may impact luminal 
breast cancer biology, determining protein-folding dynamics and stability utilizing protein 
prediction programs might offer insight as to the function of the C-terminus. First, we analyzed 
previously published work on X-ray crystallography of GATA3 to further our understanding of 
how the DBD might interact with other GATA3 motifs. To that end, protein motifs in their 
native state that fold into 3-D structures can be crystallized. The X-ray structure of these motifs 
are characterized by their folding patterns, leading to models that predict overall rigidity, 
movement, and structure. This is particularly useful for discovering known domains and also 
areas of the protein that cannot be crystallized. The GATA3 C-finger domain (amino acids 307–
370) has been successfully crystallized (Bates et al., 2008). These data illustrate the engagement 
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of the zinc finger domains along with other transcription factors, leading to self-association. In 
addition to DNA binding and interactions with other proteins, the ability to self-associate has 
been implicated in the assembly of complex protein/DNA complexes within areas of gene 
activity in other GATA family members as well (Crossley et al., 1995). In contrast, the C-
terminus has not been successfully crystalized, likely due to its lack of electron density. In these 
instances, X-ray crystallography and NMR are not effective tools in visualizing structure. 
Structures not likely to be detected by either method are usually either disordered or extremely 
soluble, or contain several charged residues (charge imbalance) (Yang et al., 2005).  
Disordered regions are regions without a tertiary structure, whose backbones tend to 
resemble either an expanded random coil or collapsed molten globular configuration. Often, 
proteins with disordered regions undergo a disorder-to-order transition upon binding to protein or 
nucleic acids (Dyson and Wright, 2002). 
To help with structural predictions, we used an online program, regional order neural 
network (RONN, http://www.strubi.ox.ac.uk/RONN), to help analyze the C-terminus since it is a 
region lacking 3-D structure. Analysis of GATA3 with RONN suggests that the extreme C- 
terminal region is highly disordered, similar to the linker between the two zinc fingers (Figure 
3.9). Likewise, there are other predicted disordered regions in GATA3 between the zinc fingers 
and within the N-tail. These regions are likely disordered in order to ensure flexible DNA 
recognition either in cis and/or trans, and they may undergo a disorder-to-order transition once 
contact is made with either neighboring TFs or DNA. Closer analysis of the C-terminal 
mutations in GATA3, particularly at residue 431, where a frame-shift mutation results in an 
elongated GATA3 (509 aa), leads to a partial loss of the disordered C-terminus region (Figure 
3.10). As a result, DNA binding stability may not occur, interrupting GATA3 binding and 
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downstream signaling. Plans for developing GATA3 mutant expression constructs are currently 
ongoing. Future approaches that will be accomplished by others will confirm protein expression 
using 293T cells, a GATA3-negative cell line. In addition, GATA3 binding will need to be 
assessed with ChIP-seq at motifs important for GATA3 signaling in breast cancer. Finally, RNA 
should be isolated from cells overexpressing these mutants in a GATA3-deficient immortalized 
breast cell line (BABE) and hybridize to expression microarrays to determine changes GATA3 
downstream signaling, as well as d-score values. 
These studies will help shed light on the impact of GATA3 mutations in the most 
commonly diagnosed breast cancer subtype, the luminal subtype. It has been understood that 
GATA3 plays a critical role in the normal development of the breast, and as a biomarker, this TF 
is significantly associated with ESR1-positive luminal breast tumors, which generally have a 
better prognosis than the other subtypes. Although the frequency of mutations in GATA3 seem 
to be enriched in luminal tumors, the consequences of such mutations are not well understood. 
These studies were initiated to elucidate the downstream effects of mutations in 3 key areas. This 
work will lay the groundwork for others in the lab to not only determine the role of the C-
terminal tail when its structure is altered by a mutational frame shift but also to better explain the 
role of GATA3 aberrations in luminal tumors.  
 
 
 
  
 
 
96 
Figure 3.1. GATA3 Protein Domains and Functions 
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Figure 3.2. GATA3 Open Reading Frame and Lentiviral Plasmid Development 
 
 
 
 
 
 
  
 
 
98 
Figure 3.3. Genomic Location of FOXA1-Reporter Sequence 
 
Note. Circles in red denote the forward and reverse primer locations. Sequence analysis and 
graphic from UCSC genome browser (https://genome.ucsc.edu/).  
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Figure 3.4. Cloning Result of FOXA1 Genomic DNA Sequence and FOXA1-luc Promoter 
Double Digest 
A  
 
 
 
 
 
 
 
 
 
 
 
B 
 
Note. Blue star denotes PCR product used for pGL4-luc cloning. A total of 6 clones contain the 
appropriate direction and size of the FOXA1 promoter sequence. 
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Figure 3.5. Normalized FOXA1 – Reporter Activity in 293T Cells  
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Figure 3.6. C–Terminus GATA3 Mutations in TCGA Data Set 
 
 
Adapted from D. C. Koboldt et al., “Comprehensive Molecular Portraits of Human Breast 
Tumors,” 2012, Nature 490(7418): 61–70. 
Note. 1–3 are mutations that will be incorporated into mutant GATA3 constructs that cover the C 
– terminus. Note that some mutations are found in both luminal A and B subtypes.  
 
 
 
  
 
 
102 
Figure 3.7. GATA3 C–Terminus: A Highly Conserved Region across Several Vertebrates 
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Figure 3.8. GATA3 Mutation Consequences 
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Figure 3.9. Predicted Disorder Regions for Wild-Type GATA3 
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Figure 3.10. Predicted Disorder Regions for Mut GATA3 (F431—Frame Shift)  
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CHAPTER 4: DISCUSSION 
Online media mogul man Tim O’Reilly once said, “An invention has to make sense in the 
world it finishes in, not in the world it started.” For Tim, being a catalyst means creating leading-
edge Internet tools to further drive innovation. A key example of this is the advent of the open 
source movement, through which Tim spurred the adoption of publicly available tools on the 
Internet. Internet companies that survived the dot-com bust in the early 2000s were limited 
financially and felt disenfranchised by the downfall of the Internet renaissance. During this time, 
creative leaders in the industry came together and advocated for the acceptance of open source 
tools that would ultimately shift the Internet business model from one of software to one of data. 
As a result, Web 2.0 was developed, which brought about inventions such as Google, mobile 
applications, and coding platforms, just to name a few. The goal for Tim and others was to create 
tools available to all, to be used in the creation of new technologies, and to breathe life into 
existing technologies that would otherwise become irrelevant. Many academic scientists will 
point out that open source platforms for data analysis have made scientific publishing of big data 
an affordable reality, allowing for the exchange and independent reproduction of analysis 
methods. Such exchanges have created an environment of innovation by affording open source 
tools in solving complex biological questions. 
In the mid 2000s, stem cell scientists successfully reprogrammed somatic cells into fully 
functional induced pluripotent cells (iPSC). The creation of this tool was a seminal leap in cell 
biology for several reasons. Basic questions about cell fate determination and differentiation 
programming had persisted within the community for decades despite various technical advances 
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that afforded better methods for answering these questions. From a practical standpoint, by the 
turn of the century a hostile environment had developed toward the scientific usage of embryonic 
stem cells. On August 9, 2001, then-president George Bush Jr. signed into law a ban on federal 
funds for embryonic stem cell research (Sandel, 2004). Scientists were also examining the 
research utility of adult stem cells, a much less contentious stem cell type, during this time. Due 
to their scarcity in tissues and lack of pluripotency, adult stem cells were deemed poor substitutes 
for embryonic stem cell research. Hence, when the Yamanaka and Thompson labs directly 
reprogrammed mouse and human somatic cells into functional iPSCs via the induction of four 
defined transcription factors, they not only circumvented the political issues surrounding 
embryonic research but also demonstrated the molecular feasibility of transforming one cell type 
into another. Reprogramming techniques employed by both labs are used today by researchers, 
including ones who have successfully published on the creation of a variety of tissues from 
unrelated cell types. 
Our goal in the present study was different from those in the pivotal iPSC studies. Instead 
of developing a dedifferentiated cell line from a somatic cell, we chose to start with a 
differentiated somatic cell line and by introducing specific transcription factors known to be 
important in breast development, to reprogram these cells directly into functional luminal-like 
breast cells. Normal luminal breast cells are differentiated cells with a low proliferative capacity 
and, like their luminal A tumor counterpart, do not grow in culture. To isolate these luminal 
epithelial cells for research studies, primary cell populations derived from normal breast tissue 
must be labeled for luminal markers and must be sorted using FACS; otherwise, the highly 
proliferative basal cells will rapidly outgrow the luminal population. The isolated luminal cell 
population does not propagate under culture conditions, so immediate use of these cells for 
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downstream applications is necessary. Working with primary cells can be a serious drawback for 
this reason.  
Others in the reprogramming field have chosen to work with primary cells that have 
undergone immortalization in order to overcome growth limitations in vitro (Huang et al., 2011; 
Ieda et al., 2010; Vierbuchen et al., 2010). We went forward with both a mouse embryonic 
fibroblast (MEF) and a normal human breast cell line (BABE) immortalized with inactivated 
Cdkn2a and by overexpression of hTERT, respectively. Both immortalization methods have 
demonstrated a lack of tumorigenicity, stable genome, and a functioning TP53/RB pathway, 
attributes that are critical for maintaining the fidelity of the primary cell line (Dove, 2015; Huang 
et al., 2011; Toouli et al., 2002).  
Initially, we hypothesized that the BABE cell line would be easier to transdifferentiate, in 
part because the BABE cell line is already a basal breast epithelial cell line. We expected that 
transdifferentiation to a luminal line would require relatively few changes, as opposed to starting 
with a cell line from a different lineage. While transductions with ESR1, FOXA1, GATA3, 
and/or PGR resulted in an increase in differentiation score (d-score) in the BABE cell line, the 
combinations with ESR1 triggered senescence, inherently limiting their use for further studies. 
TP53 and Rb are intact and functional in hTERT-immortalized cells, providing a plausible 
explanation for their growth restrictions. There are other available immortalized breast epithelial 
cell lines; one that is used more frequently is the HMLE cell line, which is immortalized via 
SV40 viral transduction of the large T antigen. HMLEs have a less differentiated phenotype and 
a lower d-score than the BABEs. However, viral inactivation of TP53 and Rb function in 
HMLEs confers tumorigenic potential (Dimri et al., 2005; Schmeichel and Bissell, 2003) making 
them an impractical cell line to work with.   
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Furthermore, our laboratory has shown that TFs can have varying effects on 
differentiation parameters between different mammary epithelial cell lines. In these experiments, 
either SNAI1 or TWIST (TFs involved in induction of EMT) were transduced into BABEs. 
Array analysis showed a higher degree of similarity to the parent BABE cell line than to less-
differentiated mammary cell lines (ME16C for example, data not shown). A similar experiment 
was also performed in HMLE cells; however, after array analysis, SNAI1 and TWIST-induced 
cells expression profiles were most similar with the claudin-low tumors (Mani et al., 2008). 
These data underscore the serious considerations around the selection of a starting cell line.  
Contrary to our initial expectations, we found that TF-induced mammary differentiation 
could be more robustly demonstrated in a cell line from a different species and lineage, mouse 
embryonic fibroblasts (MEFs). Indeed, these cells have a healthy publication record when it 
comes to the field of reprogramming. Initially used as feeder cells for the maintenance of stem 
cells, MEFs were also used in pioneering demonstrations of direct transdifferention (Huang et 
al., 2011; Vierbuchen et al., 2010). In the present study, we utilized cdkn2a-/- MEFs from a 
C57BL/6J mouse strain. These immortalized MEFs are replication competent in appropriate 
growth media. Our studies of the MEF cells, together with those of the BABEs, indicated that the 
direction and degree of differentiation changes depend on the cell environment (e.g., culture 
medium, growth factors, and hormones), interaction of cell line (cell context), and transcription 
factor combinations. These interactions are discussed in detail below. 
When devising the protocol for viral infection and media selection, there were 
considerations to be addressed. Earlier viral experiments with the BABE cell line were 
straightforward, as HuMEC media used for infection were swapped out 48 hours later for virus-
free media. In essence, we anticipated transdifferentiation would occur in media that are 
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normally used for differentiated luminal cells. However, there are no known normal mammary 
luminal cell lines, as BABE, HMLE, and ME16C cell lines are basal-like and are grown in 
serum-free HuMEC media. Keeping with the idea of HuMEC media as the most appropriate for 
the transdifferentiated MEFs, MEFs were infected with a virus in RPMI media with 10% FBS 
and then switched to serum-free HuMEC 48 hours post infection. The relative contribution to 
differentiation, as defined by the d-score, was assessed in serum-starved MEFs. Remarkably, 
serum-starved MEFs become more differentiated by d-score calculations than their parental 
counterpart (data not shown). The alternative question to address was determining the effect of 
serum undergoing transdifferentiation. To answer this, we compared the d-score between MEFs 
induced with –EFP in the presence and absence of serum (data not shown). Strikingly, the M–
EFP cell line in serum had a significantly lower d-score than the serum-free M–EFP cell line, 
suggesting that sera can negatively affect differentiation. This led us to the hypothesis that 
transitioning the induced MEFs in HuMEC media will facilitate differentiation in addition to the 
contributions of the transcription factors.  
Limitations with ectopic expression of multiple genes have been reported. While the 
selection of tissue-specific TF combinations are extremely important for successful 
transdifferentiation, the occurrence of such an event is extremely low (Brambrink et al., 2008; 
Desponts and Ding, 2010). The induction of each cell with each of the three viruses is not 100%. 
Moreover, the addition of serum-free conditions create a stressful environment, especially for 
cells lacking one or more of the TFs. In our study, serum starvation killed about 80% of the 
induced MEFs due to the reasons mentioned. For the 20% remaining, morphological changes 
became evident after 3–4 weeks, which is in contrast to the 1–2 week epithelial colony 
confirmation seen in other studies (Huang et al., 2011; Vierbuchen et al., 2010). With the lack of 
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a reporter or antibiotics for selection, we confirmed transcript and protein presence for each TF. 
After testing multiple combinations of TFs, we selected M–EFP based on morphology, d-score, 
and growth characteristics.  
The addition of hormones further enhanced the differentiation potential of the M–EFP 
cells. Although we found the treatment of MEFs with hormones did not result in any d-score 
change as compared to no treatment, the use of ligands, drugs, or other chemicals can be used 
synergistically in combination with the induction of breast-specific TFs to maximize 
differentiation potential (Brisken and O’Malley, 2010; Bussard et al., 2010; Hou et al., 2013). 
We revealed in Chapter 2 that the M–EFP cells exhibit classic epithelial structure and 
expression of markers. The structural rearrangement of actin into a cortical formation around the 
membrane is a hallmark feature of epithelial cells and also associated with CDH1 expression 
(Yap et al., 2014). We demonstrated the rearrangement of F-actin and confirmed the expression 
of CDH1 in the M–EFP cell line. The presence of breast markers supported the selection of TFs 
as ones that are involved in regulating a breast-specific phenotype. Furthermore, we 
demonstrated their gene expression profile is more like that of mouse mammary cell lines HC11 
and PyMT than of MEFs. Finally, we showed that the M–EFPs behave like a luminal breast cell, 
exhibiting sensitivity to an estrogen agonist/antagonist and secreting the milk protein beta-casein 
when stimulated by the hormone prolactin.  
While we confirmed an enrichment of several transcription factor networks involved in 
breast epithelial functional signaling, such as STAT5A and C/EBPβ, much work is still needed 
in understanding how ESR1, FOXA1, and PGR have reprogrammed MEFs. ChIP-seq 
experiments would help determine the specific promoter binding sites –EFP binds to. FOXA1 
has been shown to largely regulate where ESR1 binds to in luminal breast cancer cell lines. 
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Without the expression of FOXA1, ESR1 binds to different promoter regions (Carroll et al., 
2005). Moreover, how will silencing these genes individually impact the overall phenotype, if at 
all?  
The most difficult aspect in the creation of the artificially engineered M–EFP is its 
developmental classification compared to natural cells. It is the general consensus that in the 
mouse, a mouse mammary repopulating breast cell has low to moderate CD24 and high CD29 
levels (Mark et al., 2006; Shackleton, 2006; Stingl et al., 2006). Likewise, progenitor cells, 
which some call the bipotent population, are high for CD24 and moderate for CD29. They also 
have expression of CD61, a marker unique to the progenitor and absent in the stem cell and 
luminal subpopulations. The progenitor population gives rise to the basal and luminal lineages, 
thus expressing basal cytokeratin 5 and/or luminal cytokeratin 8/18 (Prat and Perou, 2011; Rios 
et al., 2014). Our cells exhibited positive staining for both, though only about 15% of the M–EFP 
was CD61 positive. On the d-score axis MaSC  pL, M–EFP cells are the same as normal 
mammary cells, implying that they exhibit both basal and luminal features, and so they resemble 
a developmental progenitor cell line. However, this would need to be determined by 
syngeneically transplanting GFP-labeled M–EFP cells in the fat pad of a mouse, likely at 
different developmental time points, where hormones are present/absent.   
There is lacking a luminal A cell line, which makes studying the most diagnosed breast 
cancer subtype in the lab arduous. While the M–EFP cell line is not considered a luminal A cell 
line, it has several important features in common with normal luminal cells. As an example, 
ESR1 positive breast tumors frequently become resistant to antiestrogen therapy. In the mouse, 
mammary development and carcinogenesis are less dependent on ESR1 signaling and thus are 
more difficult to study in mouse luminal tumor models. The PyMT cell line has been derived 
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from a PyMT-neu mouse tumor and expresses low levels of ESR1. Our cell line would be 
extremely useful in understanding ESR1-mediated events during mammary normal development 
and tumorigenesis. Understanding which genes these TFs regulate may also shed light on what is 
missing in terms of terminal differentiation. While the addition of hormones increased the 
differentiation of the M–EFP cells, there may be other TFs necessary to complete the process.  
In human breast development, GATA3 has been shown to be indispensable for 
alveologenesis and strongly correlates with ESR1 expression (Chou et al., 2010; Wilson and 
Giguere, 2008). Results from our initial TF screen demonstrated expressing GATA3 has 
different effects in the BABE and MEF cell lines. We observed a decrease in d-score with 
GATA3 in the MEFS and therefore were interested in determining how GATA3 function is 
affected by the cluster of mutations reported in luminal A and B tumors. GATA3 binding to 
DNA is altered by mutations in the N and C finger domains and tails, while the effects of 
mutations in the C-terminus have yet to be studied. These are often frame-shift mutations that 
would produce a C-terminal truncated protein. GATA3 mutations might be predicted to affect 
transcriptional regulation by other genes as well: GATA3 functions as a coregulator with ESR1, 
influencing the expression of ESR1-specific genes. Deciphering the relationship between ESR1 
signaling and GATA3 mutations will be critical in determining the role that GATA3 mutations 
play in ESR1-positive tumors. 
We anticipate that the creation of the M–EFP cell line will be a valuable tool in studying 
the progression of basal-to-luminal differentiation in the breast. Since the present study 
represents the first published work in this area, we hope that our technical approaches will assist 
others wishing to perform future transdifferentiation studies in breast and other tissue types. The  
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present work identified three TFs that together were able to induce critical aspects of a breast 
epithelial phenotype. Other TFs such as GATA3 may have additional roles in the differentiation 
process that have yet to be defined.  
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